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ABSTRACT 
 
Context: Reproductive aging results from depletion of the ovarian reserve and is marked by 
profound changes in hormone production and menstrual cyclicity. Age-related changes in antral 
follicle count and hormone production are well-documented.  However, follicle wave dynamics 
and associated changes in hormone production have not been evaluated as women age. 
Overall Objective: To test the overall hypothesis that major follicle wave dynamics change as 
women age, and underlie changes in hormone production as women approach menopause.   
Materials and Methods: A prospective, observational study was conducted in 58 women of 
Reproductive Age (RA; 18-35 years; n=27), Advanced Reproductive Age-1 (ARA1; 36-44 
years; n=10) and Advanced Reproductive Age-2 (ARA2; 45-55 years; n=21). The numbers and 
diameters of all follicles >2mm were recorded ultrasonographically every 2-3 days for 1 
interovulatory interval. In a subset of women (RA, n=10; ARA2, n=17) blood samples were 
collected at each visit and serum was assayed for FSH, LH, estradiol, inhibin A and B, AMH and 
progesterone concentrations. Changes in AFC, follicle wave dynamics, and hormone production 
were compared between groups (SPSS v19.0, α=0.05). 
Results: The prevalence of Follicular and Luteal Phase Major Waves (FPMWs, LPMWs) was 
not different between RA, ARA1, and ARA2 groups [FPMW: 27/27(100%), 10/10(100%), 
20/21(95%); LPMW: 10/17(37%), 3/10(30) %, 10/21(48%); P>0.050). All FPMWs were 
ovulatory. One LPMW ovulated at the time of menses in the ARA2 group; all other LPMWs 
were anovulatory. Dominant follicles in LPMWs emerged earlier (day -6, -2, -2; P=0.049), grew 
longer (11, 3, 6 days; P=0.005) and developed to a larger diameter (24, 11, 11 mm; P=0.032) in 
the ARA2 versus ARA1 and RA groups. In both RA and ARA2 groups, peak luteal phase 
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estradiol concentrations were greater in women with (139.1, 177.8 pg/mL) versus without (78.0, 
95.0 ng/mL) LPMWs (P=0.016, 0.074). In the RA group, 5/10 women developed LPMWs in 
association with higher mean (90.5 versus 53.3 pg/mL, P=0.028) and peak (139.1 versus 78.0 
pg/mL, P=0.016) luteal phase estradiol concentrations versus women in the RA group without 
LPMWs, respectively. In the ARA2 group, LPMWs developed in association with atypical 
(>200ng/mL) elevations in estradiol concentrations in 4/8 women (50%). In all women (RA and 
ARA2 combined), the max diameter of the LPMW dominant follicle positively correlated with 
luteal phase estradiol (r=0.71, P<0.01) and negatively correlated with max luteal phase LH (r=-
.52, P<0.05). In the ARA2 group, max LPMW dominant follicle diameter was negatively 
correlated with mean luteal phase progesterone (r=-.78, P<0.05). Progesterone was lower in 
women with (9.65 ng/mL) versus without (13.0 ng/mL, P=0.027) LPMWs in the ARA2, but not 
RA, group. Women in the RA group with LPMWs had a higher mean AFC >6mm and inhibin B 
versus those without LPMWs. Polyovulatory FPMWs (n=3) were detected only in the ARA2 
group and were associated with higher maximum follicular phase estradiol production and 
elevated luteal phase progesterone when polyovulation occurred at ovulation #1 of the IOI (n=2).  
Conclusions: The prevalence of FPMWs and LPMWs did not differ as women age. However, in 
women of advanced reproductive age, dominant follicles in LPMWs emerged earlier, grew 
longer and to a larger diameter. Approximately 50% of cases of LPMWs that developed in 
women of advanced reproductive age were associated with atypically high luteal phase estradiol 
and decreased progesterone. Women of reproductive age with a higher AFC >6mm and inhibin 
B were more likely to develop LPMWs.  
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Chapter 1 
GENERAL INTRODUCTION 
 The Menopausal Transition (MT) is a period of marked physiologic changes leading up 
to menopause. Women enter the MT in their mid-forties, with the final menstrual period 
occurring at the mean age of 51 (1, 2). More Canadian women belong to the 45-54 year age 
group (15.7%) than any other 10 year age group and this trend is increasing (3). Therefore, a 
large proportion of Canadian women are entering the MT. Reproductive aging in women occurs 
in association with the depletion of the ovarian oocyte population. Each oocyte is housed within 
an ovarian follicle. A decline in the number of oocytes is reflected by a reduction in follicles 
available for cyclic growth and leads to a progressive decline in Anti-Mullerian Hormone 
(AMH) and inhibin B and subsequent rise in Follicle Stimulating Hormone (FSH) (4, 5). Gradual 
changes in hormone production and follicle number are well documented during the MT. More 
recently marked variability in estrogen secretion has been reported in follicular and/or luteal 
phase (1, 6, 7). The origins of the erratic changes in estrogen production are not known. 
Unpredictable fluctuations in estrogen production during the MT are speculated to be the 
underlying cause of unwanted symptom such as hot flashes and night sweats (8). Unwanted 
symptoms occur in approximately 85% of women during the MT and can have a significant and 
negative impact on a woman’s quality of life (2, 9). It is plausible that fluctuations in hormone 
production during the MT originate from changes in follicular dynamics (10). However, 
follicular dynamics during the transition to menopause over the luteal and follicular phases have 
not been well studied.  
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We characterized and compared ovarian follicular dynamics and corresponding hormone 
secretion in women of reproductive age versus women of advanced reproductive age (i.e., 
presumed to reflect those undergoing the MT). Serial changes in major follicle wave dynamics 
over one interovulatory interval (IOI) were evaluated in a group of women from 18-55 years of 
age (n=57). Changes in hormone production during the IOI were quantified in a subset of the 
women (n=27). Our findings have been presented in 2 manuscripts. Morphologic (i.e., 
ultrasonographic) characteristics of major follicle wave dynamics in women of reproductive and 
advanced reproductive age are described in the first manuscript (Chapter 5). Corresponding 
endocrine features of major ovarian follicle wave dynamics are described in the second 
manuscript (Chapter 6).  
 We anticipate that a greater understanding of the physiological origins of profound 
fluctuations in menstrual cyclicity and hormonal production will enable the development of 
effective strategies to prevent and/or treat unwanted symptoms experienced during the MT.  
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Chapter 2 
LITERATURE REVIEW 
2.1 Human Ovarian Anatomy 
 The ovary is the master gland of the female reproductive system. The two main functions 
of the ovary are to nurture the development of healthy gametes capable of fertilization and to 
produce steroid hormones to support the development of a healthy baby (11, 12). The adult ovary 
is approximately 4 x 2 x 1 cm and oval in shape in the adult woman (13-15). A woman’s ovaries 
are situated bilateral to the uterus inferior to the left and right fallopian tubes and suspended 
within the pelvis by the suspensory ligament, utero-ovarian ovarian ligament, and broad ligament 
(13, 16, 17).  
 The outer connective tissue of the ovary is called the cortex and is covered by the surface 
epithelium and the tunica albuginea (12, 15). The ovarian medulla is the inner region which 
contains connective tissue, stromal cells, nerves, vasculature, and lymphatics (11). Growing and 
regressing ovarian follicles at various stages of development are located in the ovarian cortex 
(11). Follicles are spherical structures which house the oocytes. Each oocyte is enclosed by one 
follicle. The temporary hormone producing glands formed from follicles after ovulation (i.e., 
follicle rupture and oocyte release) are called corpora lutea (corpus luteum, singular) (12). 
Regressing, non-functional corpora lutea are called corpora albicantia (corpus albicans, singular) 
(12). Both growing and regressing luteal glands can be visualized in an ovary at any stage of the 
menstrual cycle. 
 Blood, lymph, and nerves enter the ovary through the hilus (12). The ovarian artery 
branches off from the abdominal aorta, is contained in the suspensory ligament, and enters the 
ovary via the mesovarium of the broad ligament (13, 16). The ovarian veins exit the ovary as the 
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pampiniform plexus, travel through the mesovarium and suspensory ligament to merge with the 
inferior vena cava on the right side and renal vein on the left side (13). The ovaries receive 
sympathetic and parasympathetic innervation (16). Sympathetic innervation originates from the 
thoracic spinal region, segments 10 and 11, whereas parasympathetic innervation originates from 
the hypogastric plexuses (16). 
2.2 The Hypothalamic-Pituitary-Ovarian Axis 
 The hypothalamic-pituitary-ovarian axis (HPO) co-ordinates female reproductive 
function (15). Hormones and growth factors produced from the ovaries and/or anterior pituitary 
provide positive and/or negative feedback at the level of the pituitary and hypothalamus to 
regulate hormone production during the menstrual cycle. 
 Gonadotropin Releasing Hormone (GnRH) is a decapeptide hormone produced in the 
hypothalamus (18). GnRH is released from neurons in the median eminence into the pituitary 
portal network (19). GnRH travels to gonadotrope cells in the anterior pituitary where it binds to 
G-protein coupled receptors on the plasma membrane (19). GnRH is released in a pulsatile 
manner and stimulates the production and secretion of the gonadotropins Follicle Stimulating 
Hormone (FSH) and Luteinizing Hormone (LH)  (20). Slow GnRH pulse frequencies stimulate 
FSH synthesis, whereas fast GnRH pulse frequencies stimulate LH synthesis (21, 22). FSH and 
LH are heterodimeric glycoproteins comprised of a common α subunit and unique ß subunits and 
are synthesized and secreted by the gonadotropes in the anterior pituitary (23, 24). LH binds to 
the transmembrane LH receptors located on follicular thecal cells, mural granulosa cells in the 
later stages of follicle development, and on luteinized thecal and granulosa cells of the corpus 
luteum (CL) (11, 25-28). LH binds to theca cells at all stages of follicle development to stimulate 
androgen production (11). LH binds to granulosa cells in large antral follicles (i.e., >10 mm in 
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diameter) to stimulate granulosa cell proliferation, growth, and estradiol production (11, 27, 28). 
Luteinized cells of the CL stimulate progesterone production under LH stimulation (26, 29). LH 
receptor binding initiates an intracellular cAMP-dependent signalling pathway (11). FSH binds 
to FSH receptors located on the cell surface of granulosa cells and simulates aromatase activity 
via the G-protein coupled cAMP-dependent signalling cascade (11, 30-32). FSH is suppressed by 
inhibin B, follistatin, estradiol, and progesterone (described below) (21). FSH induces the 
emergence of antral follicle waves during the menstrual cycle (11, 33). FSH increases granulosa 
cell proliferation and follicle growth (11, 30-32). Insulin Growth Factors (IGF) augment the 
effects of FSH and LH in the granulosa and thecal cells(34-37). Estradiol is an 18-carbon steroid 
hormone synthesized from cholesterol. Beginning in antral follicles 6-8 mm aromatase converts 
the androgens produced in thecal cells to estrogens, mainly estradiol (11, 30-32, 38). Estradiol is 
produced by the granulosa cells of antral follicles. Estradiol synthesis requires both FSH and LH 
acting on the granulosa and thecal cells within the follicle, respectively (reviewed in (27, 39)). 
Estradiol crosses the plasma membrane of its target cells and binds to one of two nuclear 
receptors (ERα or ERß) (40). Estradiol at low concentrations provides negative feedback to the 
pituitary which suppressing gonadotropin secretion thereby preventing continued follicle growth 
in smaller FSH-dependent follicles (27, 41-43). On the contrary, estradiol at high (i.e., 
preovulatory) concentrations is likely to exert positive feedback. However, the role estrogen in 
providing positive feedback at the hypothalamus is still uncertain (43).   
 Progesterone is a 21-carbon steroid hormone synthesized in the luteinized granulosa and 
thecal cells of the preovulatory follicle and CL (44). Progesterone production is mainly under LH 
control. Progesterone provides negative feedback to the pituitary, suppressing gonadotropin 
secretion in women during the luteal phase (20, 45).  
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 Inhibins are peptide hormones and members of the transforming growth factor-ß family. 
Inhibins are heterodimers which share a common alpha subunit linked to a ß -A (inhibin A) or ß-
B (inhibin B) subunit through a disulfide link (46, 47). Inhibin B is produced by antral follicles 
ranging from 2-12 mm in diameter (48). Inhibin A is produced by dominant follicles (i.e. 
follicles >10mm) and the human CL (49). Inhibin A and B suppress FSH secretion (46, 50, 51). 
Inhibin B production by the granulosa cells is dependent on FSH stimulation which then acts 
directly on the anterior pituitary to suppress FSH (46, 52). 
 AMH is a dimeric glycoprotein peptide growth factor and a member of the transforming 
growth factor-β family. AMH is produced by the granulosa cells in early growing follicles up 
until a diameter of 8-10 mm (48, 53, 54). Preliminary studies have postulated a role for AMH in 
antral follicle growth and selection by mediating FSH responsiveness in granulosa cells (55, 56).   
2.3 Folliculogenesis 
Folliculogenesis is defined as the process of follicle development within the ovaries (38). 
Folliculogenesis is initiated around the 24th week of embryonic development (57). A resting 
follicle requires approximately 3 months to achieve preantral status (58). A preantral follicle 
grows and matures into a preovulatory follicle over another 85 days (58). Thus, the entire 
process of folliculogenesis occurs over approximately 175 days (11, 58). Descriptions of each of 
the stages of folliculogenesis are described in more detail below. Preantral and early antral 
follicle dynamics are not the focus of this thesis and  will therefore not be discussed in detail. 
2.3.1 Pre-antral Follicle development   
Prior to puberty, follicles develop to the early antral stage of development (39). Resting 
follicles, referred to as primordial follicles, are 35-38 µm in diameter and characterized by a 
single layer of flattened granulosa cells (59). Resting follicles enter a growth phase through a 
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process called initiation (59). Initiation of the primordial follicle growth is not well understood; 
however, there are a number of identified hormones and growth factors involved (38, 60-64). 
Early growing follicles are divided into primary and secondary follicles. Primary follicles are 
approximately 46µm in diameter and are characterized by a single layer of cuboidal granulosa 
cells. At the primary follicle stage, the zona pellucida develops around the oocyte (38). A 
secondary follicle is approximately 80-100µm in diameter and contains multiple layers of 
granulosa as well as theca cells. Secondary follicles are the first to receive vascular supply (38, 
65). Secondary follicle granulosa cells begin to express FSH, estradiol, and androgen receptors 
and the differentiated theca interna cells express LH receptors. Gougeon (58, 59, 66) has used 
histological methods to describe classes of follicle growth. These classes are still accepted today 
(67). Early growing follicles (i.e., secondary) which have entered Class 1 of development are 
considered preantral follicles. Preantral follicles in Class 1 are 0.1 – 0.2 mm in diameter and  
several layers of cuboidal granulosa cells surround the oocyte (59). Class 1 preantral follicles are 
capable of the LH and FSH induced androgen and estrogen synthesis (59). Preantral follicles are 
gonadotropin sensitive but are able to grow independently of FSH stimulation (68). Preantral 
follicle development is mediated by autocrine and paracrine growth factors from the oocytes 
such as GDF-9 and BMP-15 and AMH from the granulosa cells (15, 62). 
2.3.2 Early Antral Follicle Growth 
 Early antral follicle growth comprises Classes 2 – 4. During this phase, follicles grow 
from a diameter of 0.2 to 2 mm in diameter. An antrum (i.e., fluid-filled cavity ) begins to form 
from the amalgamation of fluid collections within the follicle (38, 59). The cumulus oophorus 
complex is comprised of the oocyte surrounded by a layer of specialized granulosa cells called 
‘cumulus cells’. The cumulus oophorus can be observed once a follicle has entered Class 2. The 
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progression from a Class 2 to 4 follicle results in an increase in granulosa cell number  
approximately 3000 to 750000 (58).  
2.3.3 Late Antral Follicle Growth   
With the onset of puberty, the hypothalamic-pituitary-ovarian axis becomes activated and 
gonadotropin-dependent continued follicle development occurs. Antral follicles 2-5 mm in 
diameter are have been detected throughout the cycle in women of reproductive age (30, 69-71) 
and are dependent on gonadotropins for continued growth (58, 69, 72). Growing follicles 2-5 
mm undergo atresia in the absence of gonadotropin stimulation (30, 58). Atresia occurs via 
apoptosis, a form of programmed cell death (73). More than 99% of all growing follicles will 
ultimately undergo atresia while approximately 1% ovulate (57). An increase in FSH of 10-30% 
above the threshold is required to stimulate antral follicle beyond the gonadotropin-independent 
stage (72, 74). The magnitude of the absolute rise in FSH is variable between women (2.5 fold in 
variation) (75). If FSH falls below the minimum concentration of FSH (i.e., the FSH threshold) 
required for continued development of a follicle it is unable to maintain its growth and undergoes 
atresia (72). Granulosa cells of 2-5 mm follicles are highly mitotic under FSH stimulation (58, 
76). Therefore, a rise in FSH above the follicular threshold leads to the growth of a cohort of 
follicles referred to as a follicular wave.  
Waves of follicle development (also referred to as ‘cyclical recruitment of the follicular 
cohort’) have been described histologically (77) and  ultrasonographically in women 2-3 times 
during an interovulatory interval (IOI) (33, 70, 78, 79). An IOI is defined as the interval between 
one ovulation and the subsequent ovulation. The first phase of the IOI is the luteal phase and the 
second phase of the IOI is the follicular phase. The luteal and follicular phases are separated by 
menses. Therefore, an IOI is a menstrual cycle that has been shifted by approximately 2 weeks. 
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A wave of antral follicle development is defined as the synchronous growth of a cohort of antral 
follicles that occurs at regular intervals during the menstrual or estrous cycle. (33, 70, 78, 79). In 
women, waves of follicle development have been detected in antral follicles >5 mm (70). Waves 
of follicle development in women are comparable to follicle wave patterns described in domestic 
farm animals (80, 81). Major waves are those in which a dominant follicle is selected for 
preferential growth (described below). Minor waves are those in which a dominant follicle is not 
selected (33). Women with 3 waves of follicle development had a mean IOI length of 29 days, 
with waves emerging on days 1, 12, and 18  (day 0 = ovulation) (33). The mean IOI length in 
women with 2 waves was 27 days; wave 1 emerged on day 1 and the ovulatory wave emerged on 
day 15 (33). Repeatability of wave patterns has not been studied in women. However, 
repeatability of wave patterns has been shown to exist in 70% in cows (82).  
 Each wave of follicle development is preceded by a nadir and subsequent rise in serum 
FSH (33, 83, 84). Granulosa cells of antral follicles in the recruited cohort (i.e., 2-12mm in 
diameter) produce and secrete inhibin B (48, 50). Inhibin B acts directly on the anterior pituitary 
to inhibit FSH secretion (50, 75). In this way, the recruited cohort regulates its own growth 
(discussed below). In addition to inhibin B, AMH has been shown to play a role in follicle wave 
emergence/ recruitment (85, 86). AMH is detected in primary follicles until approximately 
10mm (48). AMH has been shown in vitro to inhibit the responsiveness of human and rodent 
granulosa cells to FSH by reducing FSH receptor mRNA and aromatase expression and in a dose 
dependent manner (55, 56, 87). Therefore, AMH is involved in preventing follicles from being 
recruited into a wave and regulating their aromatase activity (55, 56, 87). Continued research is 
required to understand the role of AMH in human follicle wave emergence. 
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 The physiologic status of luteal phase wave follicles is not fully elucidated. Results from 
early studies suggest that the proportion of healthy follicles >1 mm is lower in the luteal versus 
follicular phase (66, 76, 88). The low proportion of functional follicles in the luteal phase was 
believed to be due to suppression of FSH by the CL since a higher proportion of healthy follicles 
was observed in the late luteal phase in association with the regressing CL and rising FSH (76). 
Continued research is required to confirm these preliminary findings. 
2.3.4 Dominant Follicle Selection  
Major waves of follicle development are those in which a dominant follicle is selected for 
preferential growth.  Selection of a dominant follicle is defined as the preferential growth of one 
follicle from a wave, while the remaining antral (termed ‘subordinate’) follicles regress (33, 89, 
90). In women of reproductive age, the final wave of each IOI (i.e., in the follicular phase) is an 
ovulatory major wave. All waves of the IOI that precede the ovulatory wave (i.e., in the follicular 
or preceding luteal phase) are major or minor anovulatory waves.  Anovulatory major waves 
preceding the ovulatory wave have been detected  in 22% of women (33).  
The physiologic mechanisms underlying selection have been investigated in both humans 
and domestic farm animals. The number of follicles selected for preferential growth is dependent 
upon the amount of time (i.e., window) that FSH remains above the threshold of follicle growth 
(72, 91). The duration FSH remains above the threshold for follicle growth determines the 
number of dominant follicles selected, which is referred to as the FSH Threshold/Window theory 
(72, 74). Selection of the dominant follicle is associated with a fall in FSH.  
In ovarian stimulation therapy, exogenous gonadotropins (e.g., recombinant FSH) are 
administered beyond the normal physiologic fall in FSH. The extended FSH window results in 
the ability of multiple follicles to achieve dominance and become selected (72). FSH, in 
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association with IGF, stimulates aromatase activity in granulosa cells of the dominant follicle 
(31, 53, 92). FSH is unable to stimulate aromatase activity prior to this stage, attributed in part to 
the inhibitory effects of epidermal growth factor and AMH (56, 93).  
  Estradiol synthesis by the physiologically selected follicle is preceded by LH-stimulated 
androgen production in theca cells. Aromatization of androgens to estradiol within growing 
follicle increases local and systemic estradiol concentrations (31, 53, 94, 95). Estradiol produced 
by the dominant follicle also stimulates proliferation and development of the endometrial lining 
in preparation for ovulation and subsequent conception each cycle (39). Increased aromatase 
activity in the dominant follicle induces LH receptors on the granulosa cells (28, 96). Thus, the 
selected follicle switches from FSH to LH dependent growth (97-99). Estradiol and inhibin B 
production from the dominant follicle provide negative feedback to the anterior pituitary which 
suppresses FSH (100, 101). Thus, selection occurs in association with a decrease in FSH (102, 
103). Follicle development shifts from inhibin B/activin to inhibin A/follistatin dependence at 
the time of selection (49, 50, 104). Subordinate follicles under the dominant follicle are unable to 
continue growth in an environment of declining FSH (and have not developed LH receptors) and 
therefore succumb to atresia (101, 102). The term ‘deviation’ has been defined as the point at 
which the growth trajectories of the dominant and subordinate follicles diverge (90).  
 Two different theories exist regarding the role of FSH in the selection process. Studies in 
domestic farm animals have shown that the future ovulatory follicle had an early size advantage 
over all other follicles of the wave (81, 90). The first theory proposed that the largest follicle at 
the time of wave emergence may have the greatest number of granulosa cells and is therefore 
most capable of responding to FSH and aromatase; thus, it becomes selected. According to a 
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second theory, the follicle with the lowest FSH threshold is thought to be the first to initiate 
growth, induce LH receptors, and be selected for preferential growth (67, 72, 74, 94). 
Future dominant follicles have higher intra-follicular estradiol and IGF-II concentrations 
at the time of selection (30, 92, 105). Low Insulin Growth Factor Binding Proteins (IGFBP) 
results in increased IGF-II bioavailability which further stimulates aromatase activity. An inverse 
relationship between follicular estradiol and AMH production has been documented at the time 
of selection (48, 54, 85, 87, 106). AMH concentrations decline in antral follicles becoming 
undetectable in follicles >10mm (i.e., at selection) and has been recently shown to inhibit FSH-
induced aromatase expression in human granulosa cells in vitro (48, 54, 56). However, the 
precise mechanisms and significance of this relationship are not understood.  
Selection of a dominant follicle in a major wave occurs during the mid-follicular phase of 
each menstrual cycle in all women and during the luteal phase in 22% of women (33). The 
reasons why some, but not all, women develop major follicle waves in the luteal phase are not 
understood. The role of the CL in influencing the development of luteal phase waves has been 
investigated (107). No differences in luteal phase length, progesterone, or luteal estradiol 
production women with versus without luteal phase major waves were detected (33, 107). In 
contrast, early luteolysis in cows is thought to be responsible for the development of 2 versus 3 
follicular major waves during the IOI (108).  Cows with 3 waves have a longer inter-wave 
interval versus cows with 2 major waves (108). Luteal regression occurred later in cows with 3 
waves luteal regression occurred after the second wave had regressed and 3 days after the third 
and final (ovulatory) major wave emerged (108). Consequently, in cows with 3 waves, the 
ovulatory follicle grew for a shorter period of time and ovulated at a smaller diameter verses 
cows with 2 waves (108). In women, the day of selection was not different in luteal versus 
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follicular phase major waves and  occurred 3 days after wave emergence (i.e., at 4-5mm) (33). 
However, all waves that developed in the luteal phase were anovulatory presumably due to the 
absence of an LH surge (10, 20). In the presence of progesterone, estradiol slows GnRH and 
therefore LH pulse frequency thereby preventing ovulation (10, 20, 98). Although no dominant 
follicles in the luteal phase ovulated, it is plausible that they have the capacity to ovulate. Luteal 
phase antral follicles which have acquired the ability to synthesize estradiol in vitro have been 
detected (31). From a clinical perspective, the initiation of ovarian stimulation in the early luteal 
phase in patients undergoing In Vitro Fertilization (IVF) has resulted in the retrieval of oocytes 
and corresponding embryos (109). Therefore, healthy follicles exist in the luteal phase and can 
be stimulated for continued growth in the presence of a CL. From additional studies, it has been 
shown that ultrasonographic image attributes of dominant follicles from ovulatory waves are 
different compared to dominant follicles from anovulatory waves. (110) The clinical significance 
of the differences in image attributes, however, requires further investigation. Two and three 
waves of antral folliculogenesis during the human menstrual cycle are shown in Figure 2.2. 
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Note: A 3rd 
(anovulatory) wave 
can be seen in either 
the late luteal or 
early follicular phase 
    
 
 
Figure 2.1 Antral folliculogenesis and the corresponding changes in reproductive hormones 
during 2 waves of follicle development. Two waves of follicle development occur in 
approximately 68% of reproductive-aged women. One full menstrual cycle (i.e. the follicular 
phase and luteal phase) is shown. (Redrawn from Baerwald, et al., 2003) (33) 
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2.3.5 Preovulatory Follicle Growth  
The dominant follicle grows at an accelerated rate after selection and reaches a 
preovulatory diameter of 16-29 mm in the late follicular phase of the cycle (33, 58, 111, 112). 
Granulosa and thecal cell proliferation continues to occur in association with increased antral 
volume and (31, 58, 59). Post-selection follicle development is LH dependent and is associated 
with increasing estradiol production (97-99). Insufficient LH production prevents the dominant 
follicle from continuing to grow whereas  premature luteinisation of the ovulatory follicle and 
disrupted oocyte maturation may occur if LH is too high (113). After selection of the dominant 
follicle, estradiol causes an increase in LH pulse frequency which further drives aromatase 
activity (20). Estradiol production is positively correlated with follicle diameter whereas the 
androgens are negatively correlated with follicle diameter, (31, 32, 53, 75). The pre-ovulatory 
follicle produces >90% of estradiol in the late follicular phase (114). In addition to LH, 
continued growth of the preovulatory follicle depends on inhibin A from the follicle and other 
growth factors such as GDF-9, BMP-15, and BMP-6 from the oocyte (31, 104, 115). Inhibin A is 
produced by the dominant follicle and has been shown to increase LH-induced androgen 
production in the thecal cells (51). The persistently elevated serum estradiol concentration 
triggers an LH surge from the anterior pituitary (88, 116). The LH surge induces a re-initiation of 
oocyte meiosis as well as final maturation and ovulation of the dominant follicle.  
2.3.6 Ovulation 
Ovulation is comprised of a series of morphologic, endocrinologic, and biochemical 
changes that culminate in the release of the oocyte. The LH surge inhibits granulosa cell 
proliferation (98) and granulosa cells develop lipid droplets in the cytoplasm-evidence of 
increased steroidogenic activity (117). Granulosa cells enlarge, become disorganized within the 
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follicle wall, and begin to produce progesterone leading up to ovulation (66, 88). A sharp decline 
in estradiol and increase in progesterone production occurs at the time of the LH surge and work 
collectively to induce enzymes and proteases which degrade the follicle wall (117). The surface 
epithelium of the follicle sloughs off from the degrading tunica albuginea following the surge 
(117). The cumulus oocyte complex undergoes expansion and is released from the follicle wall 
into the follicular fluid (117). Granulosa cells dissociate from each other and the follicle wall and 
are also sloughed off into the follicular fluid (117). The LH surge also initiates an inflammatory 
signalling cascade (117). The LH surge stimulates Prostaglandin E2 and F2α synthesis in the 
granulosa cells which play an important role in ovulation by increasing blood flow to the 
preovulatory follicle, reducing blood flow to the apex of follicle rupture, and contributing to 
COC expansion (117-120). Increased white blood cells from the inflammatory (i.e., increased 
local histamines) response induce vasodilation of the capillaries surrounding the ovulatory 
follicle (26). Increased blood flow from the surrounding capillaries increases hydrostatic pressure 
in the capillaries surrounding the preovulatory follicle (118). Proteolytic enzymes degrade the 
follicle wall such that the hydrostatic pressure in the follicles overcomes the weakened tunica 
albuginea thus causing follicle rupture (118). Real time ultrasonographic observations have 
shown that expulsion of 70% of follicular fluid occurs in 0.9+0.3 minutes and the remaining 
evaluation occurs during an additional 6 minutes (121). The COC complex is released into the 
peritoneal cavity where it is taken up by the fimbriae into the fallopian tube.  
2.3.7 Anovulation 
 Anovulation occurs in approximately 10% of natural cycles, with an increasing 
prevalence as women approach menopause (1, 6, 122, 123). Three types of anovulatory follicles 
have been documented ultrasonographically: 1) simple anovulatory follicles; 2) haemorrhagic 
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anovulatory follicles (HAFs); and, 3) luteinised unruptured follicles (LUFs) (118, 124). Simple 
anovulatory follicles can grow beyond a preovulatory follicle diameter and form a cyst. Simple 
anovulatory follicles do not luteinize or haemorrhage and are characterized by thin walls and an 
anechoic follicular antrum (124). A HAF is a dominant follicle which undergoes continued 
growth and internal haemorrhaging after failing to ovulate (118, 125-127). HAFs are not 
associated with endocrine or ultrasonographic evidence of ovulation (124). The LUF syndrome 
has been defined as the lack of rupture of a preovulatory follicle, with luteinisation of the thecal 
and granulosa cells (118, 128, 129). Haemorrhage may or may not occur (130). Fibrous strands 
in the antrum are typical of hemorrhagic follicles (HAFs) beginning to clot. In contrast to a HAF, 
thickened walls are indicative of luteinisation of the LUF (118). LUFs have been better 
characterized in women and have been considered a cause of infertility (123, 131). LUFs are 
associated with a normal or blunted LH surge, and a delayed increase in serum progesterone 
(132, 133). A LUF is believed to develop as a consequence of one of the following events: 1) the 
follicle’s inability to respond to the LH surge (133); 2) an insufficient LH surge (118, 132, 134, 
135); 3) poorly timed human chorionic gonadotropin (hCG) dosing in ovulation induction (132); 
4) insufficient induction of LH receptors (136); 5) NSAID use which prevents the inflammatory 
process involved in ovulation (137); and/or, 6) stress (138). 
2.3.8 Luteal Dynamics 
The Corpus Luteum (CL) is a temporary endocrine gland that develops from the 
preovulatory follicle following ovulation. Haemorrhage into the cavity of the CL occurs in 
approximately 50% of ovulations (118). The CL with internal haemorrhage forming a cystic 
cavity is called a corpus haemorrhagicum. The presence of a central cystic cavity does not affect 
luteal function (139). 
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 Luteal development, referred to as ‘luteinisation’, is a time of significant growth, 
hypertrophy, and differentiation (29). During luteinisation, granulosa cells of the former follicle 
are transformed into granulosa lutein cells (also referred to as ‘large cells’). Similarly, the theca 
cells of the follicle develop into theca lutein cells (‘small cells’) (140). In humans, the two cell 
types remain segregated in the CL (29). Luteinized granulosa and thecal cells gain the ability to 
convert pregnenolone to progesterone through activation of the 3ß-HSD enzyme (44).  The 
granulosa-lutein cells expand up to 10 times their pre-luteal size and are the primary source of 
progesterone from the CL (29, 140). Luteinized thecal and granulosa cells also retain their 
abilities to synthesize androgens and estradiol, respectively (44). Angiogenesis represents a 
significant portion of luteal growth forming a dense network of capillaries in the CL (29). Steroid 
hormone transport from the thecal and granulosa lutein cells occurs from the dense vascular 
network in the CL (29, 44). The primary function of the CL is to synthesize and secrete 
progesterone which acts on the endometrial lining of the uterus to provide an environment 
conducive for implantation and development of an embryo. Cholesterol is delivered to the CL by 
high and low density lipoproteins for steroid hormone production (44). Estradiol suppresses LH 
secretion in the presence of progesterone. Inhibin A also is a product of the CL; however, the 
role of inhibin A is not well understood (29, 50).  
Luteinisation is regulated by autocrine, paracrine, and endocrine factors. The oocyte 
plays an important role in preventing premature luteinisation (44). Prostaglandin E2 is produced 
by the large cells of the primate CL and is important in the development and maintenance of the 
CL (141). Other regulatory factors of CL formation include LH, VEGF, IGF, BMP and cyclins 
(142-144). Progesterone production, luteal diameter, and vascular development peak in the CL 6-
7 days after ovulation (107). Luteolysis is initiated approximately 7 days after ovulation, in 
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association with a decline in production of estradiol and progesterone. Human chorionic 
gonadotropin (hCG) is produced by the conceptus and is an endocrine signal that implantation 
has occurred (144). Progesterone production by the CL continues when hCG is produced. In the 
absence of conception and hCG production the CL begins to regress during a process referred to 
as ‘luteolysis. Prostaglandin-F2α (PGF2α) is the main signal for luteolysis. In women, luteolysis is 
an ovary-mediated event (145). PGF2α is produced by the CL reduces blood flow to the CL and 
disrupts the production of progesterone thereby inducing functional luteolysis (141, 144, 146). 
Endothelin-1 is a vasoconstrictor and is involved in inhibiting steroidogenesis and inducing 
luteal regression in concert with PGF2α (144, 147). Structural luteolysis, or involution of the CL, 
occurs via apoptosis (146). PGF2α is the main signal identified to trigger apoptotic signalling 
cascades (146). 
The fall in progesterone and estradiol and increase in PGF2α cause vasoconstriction and 
atrophy of the endometrial blood supply (148). Reduced progesterone signals the release of 
lysosomal, proteolytic, and fibrinolytic enzymes which break down the stratum functionalis of 
the endometrium (148). Collectively, the lack of continued blood supply and degradation of the 
lining results in the shedding of the stratum functionalis which is referred to as menstruation  
(148).  The fall in progesterone and estradiol results in an increase in FSH production from the 
anterior pituitary, signalling emergence of the next follicular wave (20, 98).  
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2.4    Reproductive Aging 
2.4.1 The Menopausal Transition 
 The menopausal transition (MT) represents the 4-7 years in a woman’s life leading up to 
reproductive senescence (2, 122). The MT begins at the age of 45-47 and culminates in 
menopause at an average age of 51 years (77, 149, 150). The first detection of changes in 
menstrual cyclicity is the first noticeable sign of entry into the MT (122). Typically, a shortening 
of the menstrual cycle is the first detected in the MT and is due to a shortened follicular phase 
(122, 151-153). As the MT progresses, increased variability in menstrual cyclicity occurs with 
eventual lengthening of the menstrual cycle due to an increasing incidence of delayed ovulation 
and anovulatory cycles (6, 122, 150, 154-158). The current understanding of changes in ovarian 
physiology as women approach menopause is based primarily on endocrine investigations with 
limited research on follicular development. Further research to characterize age-related changes 
in folliculogenesis will provide valuable insight into changes in hormone production and 
menstrual cyclicity that occur with advancing reproductive age. 
2.4.2 The Ovarian Reserve  
 Reproductive aging occurs as a result of the depletion of the ovarian reserve (77, 149, 
159, 160). The maximum complement of ovarian follicles (i.e., approximately 7 million) is 
attained at approximately 20 weeks gestation (11). By the 24th week of gestation, germ cell 
production ends and the oogonia within each primordial follicle are arrested at the prophase stage 
of meiosis (11, 57). At birth, each ovary contains between 250,000 and 500,000 resting (non-
growing) follicles (161, 162). The total number of oocytes is reflected by the number of ovarian 
follicles and is referred to as the ovarian reserve. The ovarian reserve declines continuously until 
menopause, when there are approximately 1000 non-growing follicles per ovary (160, 161). 
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Depletion of the ovarian reserve occurs as a result of both initiation of follicular growth and 
follicle atresia (11). 
 Recently, investigators have shown that the depletion of the ovarian reserve occurs as a 
gradual acceleration in the rate follicle depletion (163, 164). This contrasts with the previously 
accepted theory in which an abrupt increase in the rate of acceleration of follicle loss occurred at 
37-38 years of age (4, 161, 164). In addition to a reduction in the ovarian reserve, the risk of 
chromosomal abnormalities in oocytes increases as women age (165, 166). Thus, both the quality 
and quantity of the ovarian reserve declines with reproductive aging (167).  
2.4.3 Hormonal Changes  
 The earliest detectable endocrine change during the MT is a decline in AMH which 
occurs in association with a shortened menstrual cycle (5). AMH is produced by granulosa cells, 
and is expressed from initiation of follicle growth until antral follicles achieve a diameter of 
approximately 8-10 mm (48, 54). AMH is correlated with the ovarian reserve because it is 
produced by all growing follicles <10mm (4). The next endocrinologic change characterized in 
women of advanced reproductive age is a fall in inhibin B and rise in FSH (5). The loss of 
inhibin B from the antral follicle wave results in a rise in FSH secretion from the anterior 
pituitary (48, 50, 75, 168-174). The monotropic rise in FSH due to the decline in inhibin B 
supports the theory that the decline in ovarian follicle number is the origin of reproductive aging 
in women (reviewed in (175)). An alternative notion to the ovarian origin theory is that an age-
related slowing of the GnRH pulse generator in the hypothalamus results in a rise in basal FSH. 
The latter theory of the origins reproductive aging has been predominantly supported in animal 
models (reviewed in (176, 177)). Evidence of hypothalamic/pituitary aging in women has been 
demonstrated in the later stages of reproductive life (158, 178-180). The rise in FSH is detected 
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in some, but not all, studies before the onset of menstrual cycle irregularity (169, 181-183). To 
date, some evidence exists to support a hypothalamic origin of reproductive aging, however the 
largest body of scientific research conducted in women supports the theory of an ovarian origin 
of reproductive aging.  
2.4.3.1 Ovulatory Cycles   
Ovulatory cycles occur in decreasing frequency throughout the transition to menopause 
(5, 6, 184). As the transition progresses, increased variability and lengthening of the menstrual 
cycle is documented in association with falling inhibin B, AMH, and rising FSH (5, 150, 154, 
156-158, 185-187). An overall gradual but marked decline in follicular phase estrogen is 
documented as women approach menopause---the fall in estrogen is one of the last endocrine 
changes to occur prior to menopause (188). Luteal progesterone production is generally thought 
to decline in women undergoing the MT with ovulatory cycles of (5, 6, 155, 182, 189). Although 
LH concentrations rise gradually as reproductive senescence approaches, intra-cycle variability 
in LH concentrations has also been documented (discussed below) (190, 191). 
 The earliest changes associated with reproductive aging in most women are a modest 
shortening of cycle length in association with a decline in AMH, inhibin B, and rise in FSH (5, 
192). The shortened menstrual cycles result from a shortening of the follicular phase (153, 192, 
193)  which, in turn, has been attributed to either earlier (153, 193, 194)  or accelerated follicle 
development (175, 192).  Shifted ovulatory follicle dynamics were attributed to the monotropic 
rise in FSH and consequently an earlier rise in estrogen (153, 172, 192, 193, 195). Elevated mid-
cycle estrogen during the MT has been shown to be associated with the development and 
ovulation of multiple dominant follicles (182, 194, 196).  
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Atypically high estrogen (>20ng/mL of the urinary estradiol metabolite EIG) in the early 
follicular phase has been associated with suppressed FSH and short (19 days) inter-menstrual 
intervals (155). A more detailed characterization of hormone production during the MT has 
revealed atypically high estrogen in the late luteal and early follicular phases of the cycle (10). 
The luteal phase pattern of secretion, termed a Luteal-Out-Of-Phase event (LOOP), was marked 
by a secondary acute rise in estrogen (i.e., >900 pmol/L), which began in the mid-luteal phase 
and lasted into the early follicular phase (10). Ovulation occurred in the early follicular phase of 
half (3/6) of the women with a LOOP event by recording an increase in serum progesterone (10). 
The origins of the acute increases in luteal phase estrogen are not known. However, it is 
speculated that major waves of antral follicle development may be responsible for the atypical 
estrogen fluctuations (10). 
 In women of advanced reproductive age with regular ovulatory/menstrual cycles, 
progesterone was normal (191, 195) or elevated in association with lower luteal LH (153). 
Increased progesterone in the luteal phase of women undergoing the MT may be explained by an 
increased incidence of polyovulation; however, notion this has not been directly investigated. An 
increase in cycle length (the interval between subsequent menses) during the MT is associated 
with anovulation and lag phases (6, 10, 197). Lag phases (10) are also referred to as delayed 
ovulations (155) or inactive phases (198, 199) and are defined as a period of time with no 
evidence of ovarian activity during an ovulatory cycle (6). Lag phases are comprised of elevated 
FSH and LH and low estrogen throughout the follicular phase (1, 10, 181, 198-200). The end of 
a lag phase is demarcated by a rise in estrogen (155, 198). Ovulatory cycles with lag phases 
preceding ovulation have also been associated with subsequently low progesterone and high 
estrogen in the luteal phase (10, 155, 200). Low luteal phase progesterone has been attributed to 
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either insufficient luteinisation (155) or luteolytic effect of estrogen (10). Ultrasonographic 
characterizations of follicle and luteal growth during ovulatory cycles with lag phases have not 
yet been conducted in women. Therefore, it is not known whether lag phases occur due to a lack 
of recruitable follicles or the inability of the antral cohort to respond to the elevated FSH. 
2.4.3.2 Anovulatory Cycles 
 The prevalence of anovulation is more closely associated with the stage of reproductive 
aging than with chronologic age. Anovulation occurs more frequently in the late versus early 
stages of the MT (5, 197, 201). Anovulatory cycles consist of either short (i.e., <21 days) or long 
(i.e., >35 days) inter-menstrual intervals (10, 155, 202, 203) that occur in the presence of 
elevated gonadotropins (1, 5, 10, 155, 180, 201). The hormonal characteristics of three types of 
anovulatory cycles have been described (158, 180). The first type of anovulatory cycle is 
characterized by a normal rise in follicular phase estrogen followed by an LH surge but no 
evidence of luteal function (10, 158, 180). This type of anovulatory cycle reflects the 
insensitivity of the preovulatory follicle to the LH surge (158). The second type of anovulatory 
event occurs when there is normal rise in follicular phase estrogen without evidence of an LH 
surge or luteal function (10, 155, 158, 180). This type of anovulatory cycle is presumed to reflect 
the inability of elevated concentrations of dominant follicle estrogen to stimulate an LH surge 
(158) or pituitary desensitization to estrogen (178-180). The third anovulatory cycle type is 
characterized by low estrogen concentrations and elevated FSH and LH (5, 158, 180, 201). Cycle 
length and estrogen production have been shown to be more variable in anovulatory versus 
ovulatory cycles (199). To date, most studies have characterized anovulation using endocrine 
assays or by recording the length of the inter-menstrual interval and the occurrence of irregular 
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bleeding patterns. Follicle growth dynamics during anovulatory cycles in women have not been 
reported.  
2.4.4 Antral Folliculogenesis  
 There is a well documented decline in AFC in association with reproductive aging (204-
208). Early emergence (153, 193, 194), and both accelerated (195) and normal (153) 
preovulatory follicle growth early in the MT have been reported from limited ultrasonographic 
data. Both normal (193, 195) and smaller preovulatory follicle diameters (153, 194) have also 
been reported. The likelihood of multiple dominant follicle growth increases as women age 
(194). The development of multiple dominant follicles in the follicular phase is believed to result 
in the age-related increase in dizygotic twinning, however an increased prevalence of 
polyovulatory cycles has not been characterized ultrasonographically (196, 209). Age-related 
changes in follicular dynamics have also been observed using animals models. Similar to studies 
conducted in women, early emergence, slowed growth and smaller peak diameter of the 
preovulatory follicle have been observed in middle aged-mares (210). As reproductive aging in 
mares continues, cycle lengthening occurs due to delayed emergence of the ovulatory wave (210, 
211).  In cows, no change in follicle wave dynamics was observed with age despite a decline in 
oocyte competence, AFC, and increased FSH (212, 213). 
2.4.5 Clinical Consequences of Reproductive Aging 
 Reproductive aging occurs in association with the depletion in the number of follicles in a 
woman’s ovaries. The ovarian reserve is associated with a woman’s fertility potential otherwise 
known as the capacity or potential to conceive. The ovarian reserve is used as a clinical marker 
of her proximity to menopause and loss of the ability to conceive, regardless of age (160, 162, 
214). Direct measurement of the ovarian reserve is not practical in the clinical setting where 
 26 
measurements need to be made non-invasively. Therefore, indirect markers of ovarian reserve 
have been developed. The Antral Follicle Count (AFC) has been defined as the number of 
follicles 2-5mm (11, 162, 215), 2-9 (216), or 2-10 mm (204, 207, 217) detected 
ultrasonographically. The AFC correlates positively with the size of the ovarian reserve (4, 208). 
Both low (218) and high (219, 220) inter-observer variability has been reported when recording 
the AFC. Thus, efforts to standardize the method to determine AFC have been made (221). High 
inter-cycle (222), intra-cycle (33) and inter-woman (215) variability in AFC has further been 
reported which emphasizes the need for standardized criteria for interpreting clinical AFC 
measurements. AMH has been shown to decline with age and thereby strongly correlates with 
the ovarian reserve and AFC (4, 223, 224). It has been generally thought that AMH showed little 
intra- and inter-cycle variability and was therefore a more reliable tool than AFC for predicting 
reproductive status (225, 226). However, more recently investigators have demonstrated 
considerable intra-cycle variability in AMH in women of reproductive age (20-32 years old) 
(227) and late reproductive age (45-55 years old) (226). The origins of the underlying changes in 
AMH are not understood. To date, AFC and AMH are thought to be the best predictors of 
ovarian reserve (62, 208, 224, 228).  
 Inhibin B is also produced by the antral follicles available for cyclic emergence into a 
wave (48, 70). Inhibin B declines in women approaching and entering into the MT (172). Inhibin 
B has been shown to independently predict early follicular phase FSH as a function of age in 
women 40-50 years old  and to a lesser extent 20-50 (when assessed between days 3 to 5) (172). 
However, the fall in inhibin B has only been consistently detected in women undergoing the MT 
therefore inhibin B is not a reliable predicator of entry into the MT (72, 172, 224).  
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 FSH was the first hormone to be measured clinically as a marker of reproductive aging 
(181, 189). FSH increases as a result of the decrease in inhibin B with the depleting ovarian 
reserve and concomitant AFC (188, 195, 229). The rise in FSH has been detected by some 
investigators before the onset of menstrual irregularity (182, 183). However, other investigators 
have reported a poor correlation between FSH and age as FSH began to increase only in women 
>40 or in the late MT (i.e. periods of amenorrhea of 3-11 months) (72, 172, 224). Inter-cycle, 
intra-cycle, and inter woman variability in FSH secretion exists (72, 197, 229, 230). Between-
woman variance in early follicular phase FSH has been shown to comprise most (65-97%) of the 
total variance by age (229). Age, ethnicity, BMI, as well as the numbers and growth dynamics of 
follciles and corresponding estrogen concentrations have been shown to affect serum FSH 
concentrations in women as they transition to menopause (33, 231, 232). Therefore, FSH alone is 
not recommended as a reliable marker for ovarian reserve (230-232). 
The Stages of Reproductive Aging Workshops (STRAW) were held in 2001 and again in 
2011 to develop a staging system to provide a standardized set of criteria for the clinical and 
scientific evaluation of reproductive aging in women (122, 183). The STRAW criteria are based 
on changes in menstrual cyclicity, hormone production and AFC that occur in women throughout 
the reproductive lifespan independent of age (122).  
The origins of the changing hormone production during progression through the STRAW 
stages are not known. It is possible that the previously-reported fluctuations in steroid hormone 
production during the MT may be due to aberrant follicle wave dynamics. It has been further 
proposed that atypical and acute changes in hormone production during the MT may be 
associated with the development of unwanted symptoms such as vasomotor symptoms (i.e., hot 
flashes, vaginal dryness, night sweats) and associated symptoms of fatigue and alterations in 
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mood. Research in this area is important for developing evidence-based, safe, and effective 
treatments to alleviate symptoms reported in women undergoing the MT. 
2.5. Ultrasonographic Imaging of Ovarian Function 
2.5.1 Ultrasound Physics  
Ultrasound waves are longitudinal mechanical sound waves. The frequency of ultrasound 
waves (>20,000 kHz) is greater than the frequency of audible sound  (20-20,000 kHz) (233).  
Sound waves are generated when an electric charge is applied to a crystal with natural or 
synthetic piezoelectric properties (233). Ultrasound waves transmitted from the crystals 
propagate through a medium (233). The frequency (the number of cycles per second, measured 
in hertz (Hz)) at which sound waves travel is dependent on the properties of the piezoelectric 
crystal (233).  
The energy (amplitude and intensity) of a sound wave becomes lost (i.e., attenuated)  as 
sound waves propagate through a medium (233). A high frequency transducer provides better 
resolution of structures in close proximity to the transducer; however, a high frequency 
attenuates very quickly and limits spatial resolution of deeper structures (14). Lower frequency 
transducers permit visualization of deeper structures---the longer wavelength that occurs as a 
consequence of using lower frequency transducers limits the spatial (i.e., axial) resolution of a 
structure (233).  
Ultrasonography enables the real-time non-invasive visualization of  stationary and 
moving structures (234). Ultrasound has been used transvaginally and transabdominally for 
clinical and research purposes to visualize structure and function (14, 70). Transvaginal 
ultrasonography is the most commonly-used clinical and research tool for imaging the female 
reproductive system. Transvaginal transducers allow the piezoelectric crystals to be placed in 
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close proximity to the ovaries and uterus. Transducers are shaped and designed to optimize the 
field of view of interest (14). Selection of a higher frequency curvilinear array transducer (i.e., 6-
9MHz) allows for a wide field of view which is necessary to visualize the reproductive tract with 
good spatial resolution (14). 
 Transducers emit timed pulses of ultrasound waves (233).  The degree of difference 
between the acoustic impedances of the first medium and the reflector medium determines how 
much of the sound wave is transmitted, refracted, or reflected (233). Scattering of the sound 
wave occurs uniformly in all directions when the wavelength is larger than the reflector (233). 
The returning echoes are weak since only a small portion of the transmitted wave is returned 
back to the transducer (233). Sound waves reflect at the angle equal to the angle of incidence 
when the sound wavelength is smaller than the reflector (233). Thus, the strength of the returning 
echo is dependent on the angle of transmission. When there is a difference in the acoustic 
impedance between 2 media transmission of some of the wave occurs and bends (233). The 
bending of a sound wave as it crosses from 1 medium to another is called refraction (233). In B-
mode, or brightness-mode ultrasound imaging, the reflected echo is converted to an electronic 
signal in a digital scan converter. The electronic signal is stored as binary digits which represent 
the amplitude of the returning signal (235). Most B-mode systems are able to detect 256 different 
amplitudes and assign the signal a grey-scale value (235). The grey-scale value of the signal is 
based on the returning amplitude of the sound wave whereas the location of the signal is based 
on the time travelled (236). Multiple pulses of ultrasonographic sound waves are sent out along 
the transducer crystal array to obtain a field of view on the display screen (236). 
There are no known adverse effects reported using diagnostic ultrasonography at 
recommended frequencies and intervals (237). Standards are in place to ensure that diagnostic 
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and research ultrasonography is as safe as possible. Thermal and mechanical indices are used by 
sonographers indicators of patient safety during an ultrasonographic examination (237). Thermal 
effects are largely due to absorption of the ultrasound energy causing attenuation of the wave 
intensity (237). Mechanical energy is converted to heat which may raise the local temperature of 
the tissues (237). The mechanical index (MI) reflects the likelihood cavitation will occur. 
Cavitation is the mechanical stress caused by the presence of small bubbles in the medium (237). 
The thermal index (TI) is the ratio between the power provided to the medium (tissue) and the 
power required to raise the temperature of the medium (tissue) 1º C (237). The MI and TI are 
displayed on the output screen so they can be monitored by the ultrasonographer. MI and TI 
values below 1.0 are considered acceptable for clinical and research purposes in humans (237). 
The ALARA (‘as-low-as-reasonably-acceptable’) principle is recommended for conducting 
ultrasonographic evaluations (237). The ALARA principle requires that ultrasonography be 
conducted only if necessary and using the lowest power for the required image.  
2.5.2 Ovary Image Characteristics 
 Echotexture refers to the pattern of echogenicity of a tissue. The stromal tissue of the 
ovary has a low-intensity, ‘grainy’ echotexture (14). Antral follicles appear as anechoic round 
structures in the ovarian stroma (13, 14). Ultrasonographic waves propagate through fluid with 
minimal attenuation or reflection. Therefore, a fluid filled follicle is visualized as an anechoic 
structure (233). Often, acoustic enhancement is seen just distal to the antral follicle because there 
is less attenuation as the sound wave propagates through follicular fluid (233). Ultrasonography 
can be used reliably to detect follicles > 4 mm in diameter.. 
Four types of ultrasonographic descriptions of corpora luteal have been described (139). 
Corpora lutea are described as having an outer wall of luteinized tissue and an inner central area 
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when visualized ultrasonographically (238, 239). The outer wall is echogenic, has an irregular 
shape, and can be distinguished from the ovarian stroma due to its echotexture (238). The outer 
wall can either be thin (<3mm) or thick (>3mm). The inner central area can be hypo-echoic or 
hyper-echoic(238). Echotextural features of the CL have been shown to reflect CL functionality 
(i.e., progesterone production) in women (238)  and domestic farm animals (240). A thin-walled 
CL with a hypo-echoic central region is associated with lower luteal progesterone (238) .  
2.6 Immunoassays  
 The most common method of measuring hormone concentrations in serum is 
immunoassays. Immunoassays involve using antibodies (or antigens) of known concentrations to 
bind to the unknown concentration of hormone in the serum. Assays operate on the principle of 
Law of Mass Action which states that at equilibrium the ratios between the concentrations of 
bound and unbound hormone (ligand) will be constant. Therefore, given a known quantity of 
binder (i.e., the antibody), the ratio of bound to free ligand at equilibrium will be quantitatively 
related to the total amount of ligand.  
2.6.1 Radioimmunoassays 
 Radioimmunoassays (RIAs) use an antibody as the binder and measure antigens or 
antigenic compounds such as hormones in serum samples (241). In an RIA, a radioactive label is 
bound to a purified antigen (what is to be measured) to function as the tracer. The basis of the 
RIA is competitive binding between the tracer antigen and the unknown test antigen or ligand 
onto antibodies (241). Often the antibody is bound to the sides of a plastic or glass tube (241). 
When a known concentration of tracer is added to a tube with an unknown amount of ligand in a 
test sample, the tracer and ligand bind competitively to the antibody (241). Competitive binding 
will eventually reach equilibrium between the bound and free phases of the tracer and ligand 
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(241). Standard curves are generated for each RIA and the percent bound tracer is compared to 
the standard curve to infer the amount of ligand in the sample (241). If a large percentage of the 
labelled antigen binds to the antibody only a small amount of antigen was present in the sample 
being assayed; the percent bound tracer and amount of ligand present in the sample are inversely 
related (241). 
2.6.3 Enzyme-Linked Immunosorbent Assays 
 Enzyme-Linked Immunosorbent Assays (ELISAs) are a subgroup of enzyme 
immunoassays in which an enzyme is coupled to an antibody, antigen, or hapten such that the 
immunological and enzymatic activities are retained (241). In an ELISA, the tracer is an enzyme 
bound to an antibody which contrasts RIA, where there is an identical molecule to the ligand 
which has a radioactive isotope substituted in or attached to the ligand. An ELISA involves the 
sequential addition of reagents separated by wash steps to remove any unbound reagents (241, 
242). Immunoassays utilize the binding properties of an antigen to its antibodies which can either 
be antigen specific (monoclonal) or less specific binding to different antigens (polyclonal) (241). 
The ligand is measured through detection of color after a chromophore reacts with the enzyme 
(241). Three different forms of competitive ELISAs exist- direct, indirect, and sandwich 
ELISAs. However, all forms have certain common features: 1) the unknown compound (ligand) 
is attached to a solid surface; 2) a detection antibody linked to an enzyme is added and washing 
removes any unbound antibody; and, 3) the amount of bound antibody is quantified by 
measuring the colour of the bound antigen-antibody-enzyme (242). To quantify the amount of 
ligand (antigen) the colour change can be read using a spectrophotometer. A spectrophotometer 
transmits light at a specific wavelength through the fluid in the wells and measures the amount of 
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absorption of the light by the color of the enzyme which correlates with the amount of unknown 
ligand (241).  
 A direct ELISA is the simplest ELISA (242, 243). The ligand (unknown compound or 
antigen) to be measured is diluted in a buffer and then added to the plate or well (242, 243). The 
ligand passively adsorbs to the plate surface during the incubation period (242, 243). Uncoated 
(unbound) antigen is washed away. The conjugated antibody-enzyme tracer is added which binds 
directly to the antigen adsorbed to the plate or well (242, 243). After incubation, free conjugate is 
washed away and a substrate (i.e., chromophore) is added (242, 243). The enzyme in the 
conjugate catalyzes the reaction in the chromophore/substrate solution, yielding color (242, 243). 
The reaction is stopped and is quantified using a spectrophotometer.  Direct ELISAs are most 
commonly used for immunohistological staining (243). 
 An indirect ELISA involves addition of the sample with unknown ligand (antigen) to the 
plate or well. The well is then incubated allowing the antigen can adsorb to the solid phase (242). 
Unlabelled antibodies are added in a buffer solution which specifically bind to the antigens 
during an incubation period (242). After another washing step to remove any free antibody, the 
conjugate (what will be detected / measured) diluted in a buffer solution is added. The mixture 
incubates to allow the conjugate to specifically bind to the antibodies which are bound to the 
antigens adsorbed to the solid phase (242). After a wash step, the substrate/chromophore is 
added, binds to the conjugate, is stopped and the colourmetric reading is completed (242).This 
test is used to detect the presence of antibodies in sera and is most suitable for diagnostic 
purposes to screen large numbers of samples (242). A disadvantage to this method is that there 
can be increased risk of non-specific binding in different sera with the second antibody (244). 
 34 
 A sandwich ELISA begins with the adsorption of antibodies to the solid phase referred to 
as capture antibodies (242, 243). After a wash, the antigens are diluted in blocking buffer and 
added to the antibodies in the wells on the plate (242, 243). The antigens attach to the antibodies 
bound to the solid phase (242, 243). Following another wash, the enzyme-antibody conjugate 
within the blocking buffer is added and incubated (242, 243). Excess conjugate is washed away 
and chromophore is added to react with the enzyme (242, 243). The reaction is thereafter stopped 
and read with a spectrophotometer (242, 243). The disadvantage to this method is that the ligand 
of interest (or antigen) must have two binding sites, or epitopes, because it must bind to both a 
capture and tracing antibody (242).  
2.6.3 Validation 
 Determining how well an immunoassay performs is critical and must be identified when 
reporting results. Sensitivity, range, intra- and inter- assay precision, linearity (assaying samples 
under different dilutions), recovery (assaying at increasing known ligand solutions), and 
specificity should be determined and reported for assays used in labs (245-247) . All ELISA 
results are compared with the RIA results. Correlations between the two results are made with a 
correlation statistic to determine if there are differences between the values (246). Sensitivity, 
specificity, and precision are characteristics of all immunoassays that contribute to accuracy 
(246). 
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Chapter 3 
 RATIONALE 
The number of women entering the MT is increasing (3). The physiologic changes 
women undergo as they progress through the MT are not fully understood. The current 
understanding of the MT is limited to changes in AFC, menstrual cyclicity and hormone 
production. Profound variability in menstrual cyclicity and hormone production has been 
observed; however, the physiologic origins of these changes are not understood. Follicles are the 
functional units of the ovary. Follicles produce hormones which act to regulate cyclic changes in 
reproductive function throughout life. Therefore, it is plausible that the origins of the profound 
variability in hormone production can be elucidated by characterizing the changes in follicle 
dynamics. A greater understanding of the physiologic origins of the changes in hormone 
production during the MT will enable the development of more effective preventative and 
therapeutic strategies for minimizing hormonal fluctuations. Acute elevations in estradiol 
secretion during the MT have been proposed to be associated with unwanted symptoms (in 
particular vasomotor symptoms) and may also place women at greater risk for estrogen-
dependent reproductive cancers. Alleviating unwanted symptoms and health risks associated 
with atypical hormone production during the MT will ultimately improve the quality of life of 
women as they age. 
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Chapter 4 
 GENERAL OBJECTIVES AND HYPOTHESES 
The overall objective of this research was to characterize the age-related changes in 
major follicular wave dynamics and corresponding changes in reproductive hormone secretion 
throughout the human menstrual cycle. The first objective was to compare the prevalence and 
growth dynamics of major follicular waves in women as they age (Chapter 5). The second 
objective was to characterize and compare hormone production associated with major follicular 
wave dynamics in women of reproductive versus advanced reproductive age (Chapter 6).  
The general hypotheses tested were: 1) changes in major follicular wave dynamics would 
occur with age; and, 2) changes in reproductive hormone production would occur with age in 
association with major follicle wave dynamics. The null hypothesis was that follicle wave 
dynamics and associated hormone production were the same across age groups. 
 
The following specific hypotheses were tested: 
A. Study 1 (Chapter 5): Age-Related Changes in Major Ovarian Follicular Wave Dynamics: 
Morphologic Characteristics. 
1.Follicular Phase Major Waves: The dominant follicle of the Follicular Phase Major 
Wave (FPMW) would emerge, become selected, and ovulate earlier in women of 
advanced reproductive versus reproductive age; and, 
2. Luteal Phase Major Waves: In women of advanced reproductive age, the prevalence of 
(LPMWs) would not differ, the growth dynamics of LPMWs would differ, and 
anovulatory or ovulatory LPMWs would develop. 
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B. Study 2 (Chapter 6): Age-Related Changes in Major Ovarian Follicular Wave Dynamics: 
Endocrinologic Characteristics, 
1. Follicular Phase Major Waves: Elevated serum estradiol and inhibin A would be 
detected in advanced reproductive versus reproductive-aged women in association 
with a greater incidence of codominance and/or polyovulation; 
2. Luteal Phase Major Waves:  Atypically high estradiol and inhibin A secretion as well 
as decreased progesterone production would be associated with the development of 
LPMWs in women of advanced reproductive age; and, 
3. Major Waves and Markers of Ovarian Reserve: Greater luteal phase inhibin B and 
AMH concentrations would be detected in women with versus without LPMWs, 
irrespective of age. 
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Chapter 5 
 
 Age-Related Changes in Major Ovarian Follicular Wave Dynamics:  
Morphologic Characteristics 
 
Heidi K Vanden Brink, BSc, Donna R Chizen, MD, Angela R Baerwald PhD 
 
Department of Obstetrics, Gynecology & Reproductive Sciences, College of Medicine, 
University of Saskatchewan, Saskatchewan, Canada 
 
5.1 Abstract 
Context: The menopausal transition results from depletion of the ovarian reserve and is marked 
by profound changes in hormone production and menstrual cyclicity. Follicle wave dynamics 
have not been studied in women during the menopausal transition.  
Objective: To test the hypothesis that major follicular wave dynamics change during the 
transition to menopause.  
Materials and Methods: A prospective, observational study was conducted in 58 women of 
Reproductive Age (RA; 18-35 years; n=27), Advanced Reproductive Age-1 (ARA1; 36-44 
years; n=10) and Advanced Reproductive Age-2 (ARA2; 45-55 years; n=21). The numbers and 
diameters of all follicles >2mm were reported ultrasonographically every 2-3 days for 1 
interovulatory interval. Changes in AFC and follicle development were compared between 
groups (SPSS v19.0, α=0.05).  
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Results: The prevalence of Follicular and Luteal Phase Major Waves (FPMWs, LPMWs) was 
not different between RA, ARA1, and ARA2 groups [FPMW: 27/27(100%), 10/10(100%), 
20/21(95%); LPMW: 10/17(37%), 3/10(30) %, 10/21(48%); P>0.050). All FPMWs were 
ovulatory. One LPMW ovulated following menses in the ARA2 group; all other LPMWs were 
anovulatory. Dominant follicles in LPMWs emerged earlier (day -6, -2, -2; P=0.049), grew 
longer (11, 3, 6 days; P=0.005) and developed to a larger diameter (24, 11, 11 mm; P=0.032) in 
the ARA2 versus ARA1 and RA groups.  
Conclusions: The prevalence of FPMWs and LPMWs does not differ as women age. However, 
in women of advanced reproductive age, dominant follicles in LPMWs emerge earlier, grow for 
a longer period of time and to a larger diameter compared to younger women.  
Keywords: Aging - Ovarian follicle - Menstrual cycle - Ovary - Antral follicle count 
 
 
5.2 Introduction 
 The transition to menopause is a time of profound changes in reproductive physiology 
and menstrual cyclicity (150, 231). The Menopausal Transition (MT) begins, on average, in a 
woman’s mid-forties and lasts approximately 4-7 years (150). Menstrual irregularity is currently 
the hallmark feature signalling the onset of the MT (122, 150, 157). As a woman enters the MT, 
a shortening of the menstrual cycle occurs (150-153, 157, 182). With progression through the 
MT, menstrual cycle variability increases and cycles eventually lengthen until the final menstrual 
period (122, 150, 156-158, 186, 248). Documentations of cycle variability associated with 
reproductive aging in women are consistent with those reported using animal models of 
reproductive aging (211, 249, 250).  Changes in menstrual cyclicity during the MT result from 
the age-related decline in ovarian function. Throughout a woman’s lifetime, there is a continuous 
depletion in the number and quality of oocytes, referred to as the ovarian reserve (77, 149, 159, 
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162, 163, 175). The  reduction in the ovarian reserve and resultant changes in reproductive 
hormone production culminate in menopause at approximately 51 years of age when the number 
of follicles comprising the ovarian reserve falls below a critical level of approximately 1000 
(160, 161).  
  It is not possible to quantify the numbers of primordial follicles (and oocytes within) 
using currently-available imaging techniques. However, the ultrassonographic determination of 
Antral Follicle Count (i.e., AFC) has been shown to accurately reflect the ovarian reserve (122, 
204, 207). The AFC has been defined as the number of follicles 2-5 (58),  2-9 (216), or 2-10 mm 
(207, 217, 221, 251), visualized using transvaginal ultrasonography (122). The depletion of the 
ovarian reserve and concomitant decline in AFC with age leads to a decrease in the amount of 
circulating Antimullerian Hormone (AMH) and inhibin B (168, 170, 172, 252). AMH is 
produced by granulosa cells of pre-antral and early antral follicles (48, 253), and thereby declines 
with age (208). AMH is positively correlated to AFC, and these 2 endpoints have been shown to 
be the best predictors of ovarian reserve and reproductive status (85, 224, 225, 254). Inhibin B is 
thought to be produced by the antral follicles of each follicular wave during the menstrual cycle 
(48). Inhibin B secretion inhibits FSH production which mediates follicular regression and 
selection of a dominant follicle (in cases of major follicular waves) (172). Thus, a loss of inhibin-
mediated negative feedback on gonadotropin production as a woman ages results in a rise in 
systemic FSH.  
 Atypically high estradiol secretion during the luteal phase has been documented in 
addition to gradual changes in inhibin B, AMH and FSH during the MT (10, 155, 255). The 
luteal phase pattern of estradiol secretion, termed a Luteal-Out-Of-Phase (LOOP) event, has been 
characterized as an atypically high rise in estradiol, which begins in the mid-luteal phase and 
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persists into the early follicular phase (10). Ovulation, defined as a positive LH surge and 
subsequent progesterone rise, occurred in the early follicular phase of half (3/6) of the women 
with LOOP events (10).  Documentation of atypically high estradiol secretion and 
endocrinologic evidence of ovulation have important clinical implications for women as 
increased estrogen exposure is associated with reproductive cancers (201) and unwanted 
symptoms experienced during the MT (256). The origin of atypical luteal phase estradiol 
secretion, however, is not known.   
 Several studies have been conducted to characterize the decline in AFC and altered 
endocrine environment during the MT. However, little is known about changes in ovarian 
follicle dynamics that occur with reproductive aging. It has been shown that antral follicles in the 
follicular phase of regularly cycling women in their early to mid-forties emerge earlier (153, 193, 
194), and grow at either an accelerated (172, 192), slowed (194), or normal (153) rate when 
observing the follicular phase of regularly cycling women of reproductive age. It has also been 
reported that women >45 years were twice as likely to have multiple dominant follicles >10mm 
throughout their cycle; however, the origin and fate of the multiple dominant follicles was not 
ascertained (194). Ovulation at a smaller preovulatory follicle diameter and an increased 
incidence of polyovulation has also been associated with reproductive aging (153, 196). 
Anovulatory cycles and cycles with lag phases (delayed emergence of the ovulatory follicle) 
have been demonstrated endocrinologically to become more frequent across the MT; however 
limited ultrasonographic data are available to confirm these findings (1, 10, 155, 194). Few 
studies have been conducted to characterize the serial growth of individual follicles during the 
entire menstrual cycle, in particular during the luteal phase. Furthermore, luteal development 
during the MT has not been characterized.   
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 Two-three waves of antral follicles develop during each menstrual cycle in women of 
reproductive age (70). Major waves have been defined as those in which selection and 
preferential growth of at least 1 dominant follicle occurred (33). Minor waves are those in which 
selection was not manifest. Currently, it is not known whether wave patterns of antral follicle 
development over the menstrual cycle change during the transition to menopause. It is plausible 
that major follicle waves developing in the luteal phase may be responsible for the atypically 
high estradiol secretion during the MT (10, 155, 255). A greater understanding of the origins of 
atypical hormone production during the MT has important clinical implications for preventing 
the associated health risks women face during the MT. Continued research to elucidate the 
physiologic changes occurring during the MT will enable the development of safe and effective 
strategies for treating unwanted symptoms and thereby optimize the quality of life of women as 
they age. The growing proportion of Canadian women over the age of 45 years makes research 
in this area is particularly relevant (257).  
 The objective of the present study was to characterize major follicular wave dynamics as 
women age. The following hypotheses were tested: i) the dominant follicle of the follicular phase 
major wave would emerge, become selected, and ovulate earlier in women of advanced 
reproductive versus reproductive age; ii) the prevalence of luteal phase major waves would not 
differ with age; iii) the growth dynamics of Luteal Phase Major Waves (LPMWs) would differ 
with age; and iv) anovulatory and ovulatory LPMWs would develop in women of advanced 
reproductive age.  Our hypotheses were based on previous research conducted by our group and 
others, as well as clinical observations in women of advanced reproductive age undergoing 
natural cycle monitoring or ovarian stimulation for the treatment of infertility.  
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5.3 Materials and Methods 
 A prospective, observational study was conducted from 2006-2011. The study protocol 
was approved by the Biomedical Research Ethics Board at the University of Saskatchewan and 
the Strategic Priorities and Planning Committee of the Saskatoon Health Region.  All study 
procedures were conducted in accordance with the Tri-Council Policy Statement on the Ethical 
Conduct for Research Involving Humans. Informed consent was obtained by all participants 
before study procedures were initiated.  
5.3.1 Study Participants 
 Women were recruited using electronic and paper advertisements posted throughout the 
Saskatoon Health Region, University of Saskatchewan, and Women’s Midlife Health Centre of 
Saskatchewan. Inclusion criteria included: 18-55 years of age; a normal complete blood count; 
and normal serum TSH, prolactin, and β-hCG findings. To be eligible, women aged 18-44 had a 
history of regular menstrual cycles (i.e. 21-45 days long). However, women aged 45-55 were 
eligible if they had a history of no more than 12 months amenorrhea. Exclusion criteria included: 
use of any type of hormone therapy within 3 months of study participation, current smokers, 
documented ovarian failure and/or currently-diagnosed infertility of unexplained or female 
origin, medical conditions or use of medications known or suspected to interfere with 
reproductive function, presence of only one ovary, ovaries which we were unable to visualize 
ultrasonographically, pregnancy, lactation, and/or participation in an investigational drug trial 
within 30 days of study participation.   
 Seventy-one women were enrolled in the study. Only ovulatory cycles were included in 
our analyses. Data from 13/ 71 women enrolled in the study were excluded for the following 
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reasons: pregnant during the study (n=1), unable to complete study procedures for personal 
reasons (n=7), anovulatory cycles documented during the study (n=3), and failure to meet 
inclusion criteria following pre-study screening (n=2). Data from the remaining 58 participants 
were evaluated. Women were divided into the following age categories: reproductive age (RA; 
aged 18-35), advanced reproductive age 1 (ARA1; aged 36-44), and advanced reproductive age 2 
(ARA2; aged 45-55). The age of the RA group was chosen to represent a reference group of 
ovulatory women in the peak reproductive stage of life. The ARA 1 group represented women 
during the late reproductive stage of life (36-44 years of age).The ARA2 age group was chosen 
to represent ovulatory women undergoing the transition to menopause.  
5.3.2 Study Procedures 
 Transvaginal ultrasonography was conducted to evaluate ovarian function in each 
participant (6-9MHz curvilinear array transducer, Ultrasonix RP, Burnaby, BC, Canada).  
Ultrasound exams were performed by 1 of 2 investigators (ARB, HKV). Scans were initiated in 
the early-mid follicular phase (i.e. day 8-15) and continued every Monday, Wednesday, and 
Friday for one complete Interovulatory Interval (IOI). An IOI was defined as the time period 
from one ovulation to the subsequent ovulation. When a preovulatory follicle was detected at 14-
16mm, ultrasound exams were performed daily in order to determine the day of ovulation. 
Ovulation was defined as the disappearance of a dominant follicle seen on the previous day and 
subsequent visualization of the corpus luteum (CL) (107, 258). 
 During each examination, video clips of each ovary in both the sagittal and transverse 
planes were recorded. All video clips were reviewed retrospectively by a single investigator 
(HKV) using customized imaging software (Santesoft DICOM Editor Version 3.1.0). All 
follicles >4 mm and the number of follicles >2 mm were tabulated at each visit for each 
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participant. Measurements were taken separately for the right and left ovaries. Follicle diameter 
measurements were made when the longest and widest follicle dimensions were observed. The 
diameter of each follicle <10 mm was calculated as the average of the length and width. When a 
follicle achieved a mean diameter of 10 mm in one plane, the same follicle was identified in the 
video clip recorded in the other plane, and the length and width measurements were made again. 
Thus, the diameter of follicles >10 mm was calculated as the overall mean of the average 
diameter measurements in the sagittal and transverse planes.   
 Serial changes in follicle diameter during the IOI were tabulated using both the ID and 
NonID methods, as previously described (33, 70, 259, 260). Briefly, the ID method involved 
sketching all follicles >4 mm in each ovary (70, 259-261).The day-to-day identities of all 
individual follicles which grew to >7 mm during the IOI were retrospectively identified and 
growth profiles were graphed for each participant (Windows Office Excel, 2003). In contrast, the 
NonID method involved sorting the diameters of all follicles >4 mm in decreasing order at each 
visit. Each day of the IOI comprised a single row of a word processing spreadsheet (Windows 
Office Excel, 2003) and each column represented a single follicle that developed during the IOI. 
It was assumed that the largest, second largest etc. follicles on the first day of the IOI became the 
largest, second largest etc. follicles on all subsequent days. No sketches of the ovaries were made 
for the NonID method, and the day-to-day identities of individual follicles were not determined. 
The growth profiles of all individual follicles, as determined using the NonID method, were then 
graphed.   
 The numbers of follicles (i.e. AFC) across the entire IOI were reported for each 
participant for the following size categories: 2-5 mm, 2-9 mm, 2-10 mm, >4 mm, >5 mm, and  
>6 mm. Major follicular waves were characterized by quantifying changes in both the number 
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and growth dynamics of individual follicles. Minor waves were not characterized in the present 
study.  
 Diary cards were completed by participants to record adverse events and medications 
taken during the study.   
5.3.3 Definitions 
 A Dominant Follicle (DF) was defined as a follicle which grew to a diameter of >10 mm 
and exceeded the next largest follicle by at least 2mm.  A major follicle wave was defined as an 
increase followed by a decrease in the total number of follicles >6mm occurring in association 
with the emergence of at least one dominant follicle. An increase in follicle number was defined 
as at least 2 increasing data points (1-3 days between data points) between a nadir and a peak. In 
13% of cases an increase in AFC was not evident in follicles > 6 mm. In these cases the increase 
in follicle number was characterized using follicles > 4 or 5 mm. A decrease was defined as 2 
decreasing data points (1-3 days between data points) following the preceding rise in AFC of the 
wave. In 14% of all major waves the decrease in AFC was not evident in follicles > 6mm, 
therefore the decrease was characterized using AFC 2-9, 2-10, >4 or >5 mm.  
 The day of wave emergence was defined as the day that the DF was identified 
retrospectively at 4 or 5mm. A codominant follicle (CF) emerged from the same wave as the 
DF, attained a diameter of >10 mm, and exceed the next largest follicle by >2 mm. Subordinate 
follicles (SF) were defined as all other follicles that emerged in association with the AFC rise 
from which the dominant follicle emerged. The first subordinate (SF1) was considered the 
second largest (non-dominant) follicle in the wave, SF2 the third largest, etc. The day of 
selection of the DF was defined as the day immediately preceding a difference in growth 
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trajectories between the DF and SF1 (i.e., the DF continued to grow while the SF1 initiated static 
or regressing phase).  
The Follicular Phase (FP) was defined as the period of time from the first day of menses 
until the last day the preovulatory follicle was observed. The Follicular Phase Dominant 
Follicle (FPDF) emerged from the Follicular Phase Major Wave (FPMW).  The Luteal Phase 
(LP) was defined as the period of time from the day of ovulation until the day before the first 
day of menses. A Luteal Phase Dominant Follicle (LPDF) emerged from the Luteal Phase 
Major Wave (LPMW).  
A lag phase was defined as a period of no follicular development >6 mm for greater than 
20 days from menses or ovulation.  
5.3.4 Statistical Analyses  
 The primary endpoint was follicle diameter. Secondary endpoints included follicle 
number, growth intervals, cycle lengths, and single point measures of physiologic interest. 
Follicle diameter and number data were centralized to the first day of ovulation for statistical and 
illustrative purposes. Normality was assessed for all endpoints using Shapiro-Wilks tests. Non-
parametric tests were used for all analyses because our data were not normally distributed. 
Continuous variables at predetermined times (i.e., on specific days of the IOI; over the entire 
IOI, follicular phase, or luteal phase) were compared between groups using Mann-Whitney U 
tests and Kruskal-Wallis tests. When significance was detected using Kruskal-Wallis tests, post 
hoc comparisons were made using Mann-Whitney U tests with a Bonferonni adjustment. 
Fisher’s Exact tests were used to compare categorical endpoints across age groups. Continuous 
data are reported as median (interquartile range). Categorical data are reported as percentage of 
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age group (proportion of group).  Alpha was set at 0.05. All statistical analyses were conducted 
using SPSS (IBM, Version 19.0). 
5.4 Results 
5.4.1 Participant demographics 
 Participant demographics and cycle features are compared in Table 1. Age, gravidity, and 
parity increased across age groups (P <0.001). BMI was lower in the ARA1 versus RA and 
ARA2 groups (P =0.033). The prevalence of past smokers was not different across age groups 
(P>0.05). Mean IOI, follicular phase and luteal phase lengths did not differ among age groups 
(P>0.05). 
Table 5.1 Participant Demographics and Cycle Characteristics Compared between Age Groups 
 
 
 
 
 
 
a,b,c Within rows, values with different superscripts are different. Day 0 = day of first ovulation. 
 
 
 
 
n=21n=10n=27
RA ARA1 ARA2 P-value 
Demographics
Age (years) 27.0a (18.0-35.0) 40.0b (36.0-43.0) 48.0c (45.0-50.0) <0.001
BMI (kg/m2) 25.6 a (21.0-35.0) 22.4b (21.0-30.0) 25.9a (20.0-33.0) 0.033
Gravidity (#) 0a (0-3) 2b (0-5) 3b (0-5) <0.001
Parity (#) 0a (0-3) 2b (0-4) 2b (0-4) <0.001
Ever-smoker (n) 1 0 2 >0.050
Cycle Characteristics
IOI (days) 27.0 ( 25.0-30.0) 26.5 (23.0-32.0) 26.0 (17.0-48.0) 0.545
Follicular Phase  
Length (days) 14.0 (11.0-25.0) 14.0 (10.0-18.0) 13.0 (4.0-33.0) 0.465
Luteal Phase 
Length (days) 14.0 (5.0-16.0) 13.0 (10.0-15.0) 13.0 (7.0-17.0) 0.602
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5.4.2 Follicular Wave Dynamics 
 Examples of follicular wave profiles that developed in individual participants within each 
age group are shown in Figure 5.1. One (36/58, 62%) or two (22/58, 38%) major follicular waves 
were observed during the IOI in all women evaluated. Cycles in which LPMWs developed and 
those in which LPMWs were not detected are compared within and between age groups.  The 
prevalence of major waves in the follicular and luteal phases is shown in Table 5.2. In the RA 
group, 27/27 women developed an ovulatory FPMW, while only 10/17 women developed an 
anovulatory LPMW.  Similarly, in the ARA1 group, 10/10 women developed a FPMW 
(ovulatory) and 3/10 women developed a LPMW (anovulatory).  In the ARA2 group, 20/21 
women developed a FPMW (ovulatory) and 10/21 women developed a LPMW (anovulatory). 
The prevalence of FPMWs and LPMWs did not differ among age groups (P >0.05; Table 5.2, 
supplemental). In 22/23 cases (irrespective of age group), LPMWs were anovulatory. In the 
remaining case (1/23), one woman in the ARA2 group developed a LPMW which resulted in 
ovulation at the time of menses; ovulation of the LPMW was confirmed by ultrasonographic 
visualization of the CL. A subsequent FPMW was not observed in this participant (Figure 2).  
Lag phases were documented in 2/21 (10%) women in the ARA2 group. An example of a 
lag phase in shown in Figure 5.3.  
 
Table 5.2 Prevalence of major follicle waves during the IOI 
 
 
 
RA ARA1 ARA2 P-value 
Follicular Phase Major Waves 100% (27/27) 100% (10/10) 95% (20/21) >0.05 
Luteal Phase Major Waves 37% (10/17) 30% (3/10) 48% (10/21) >0.05 
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Figure 5.1 a-f Examples of follicular profiles in individual participants among each of the age 
groups. Examples from the RA (a,b), ARA1 (c,d) and ARA2 (e,f) groups are shown. Data are 
centralized to day of first ovulation (i.e., day 0=1st ovulation). OV=ovulation. The largest 3 
individually-identified follicles in each wave are shown (as determined using the ID Method). 
The solid bar along the x-axis represents the days when the CL was visualized. The solid vertical 
line represents the first day of menses 
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Figure 5.2: An example of a follicle growth profile from a woman in the ARA2 group. The IOI 
was 17 days long. No FPMW was observed during the IOI. Data are centralized to day of first 
ovulation (day 0). OV = ovulation. The solid bar along the x-axis represents the days when the 
CL was visualized. The solid vertical line represents the first day of menses. 
 
 
 
 
 
 
Figure 5.3 An example of a follicle growth profile from a woman in the ARA2 group. A lag 
phase (i.e., period of time in which no follicles >6mm developed) was detected from ovulation 
and lasted 38 days. This participant had a 48 day IOI. Data are centralized to day of the first 
ovulation. OV = ovulation. The solid bar along the x-axis represents the days when the CL was 
visualized. The solid vertical line represents the first day of menses. 
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5.4.2.1 Luteal Phase Major Waves (LPMWs) 
Characteristics of LPMWs are shown in Table 4. Luteal phase major waves emerged 
earlier (relative to the day of the first ovulation) in ARA2 versus RA group (day -6.0, -2.0, 
respectively; P=0.049).  Similarly, the dominant follicle of the LPMW was larger in the ARA2 
versus RA group (10.0 versus 6.5 mm, respectively; P=0.022; Table 4) on the day of the first 
ovulation. The ovulatory follicle from the previous follicular phase (i.e., preceding ov #1) on the 
day of LPMW emergence tended to be smaller in the ARA2 versus RA and ARA1 groups 
(P=0.066).  
The day of selection (2.0, 3.0, 0.0; P=0.180) and diameter of the DF (9.0, 10.5, 9.7 mm; 
P=0.631) and SF1 (8.0, 7.5, 7.0 mm; P=0.248) on the day of selection were not different in RA 
versus ARA1 versus ARA2 groups (Table 5.3).  The DF of the LPMW grew for a longer period 
of time (11.0, 6.0 days; P=0.005) and to a larger diameter (24.0, 11.0 mm; P=0.032) in the ARA2 
versus RA group.  In contrast, the SF2 of the LPMW developed to a smaller diameter in the 
ARA2 versus RA group (6.0, 7.5 mm; P=0.013) 
 
 
 
 
 
 
 
 53 
Table 5.3 Characteristics of Luteal Phase Major Waves 
 
 
 
 
 
 
 
 
 
 
a,b,c Within rows, values with different superscripts are different. Day 0 = day of first ovulation. 
 
5.4.2.2 Follicular Phase Major Waves (FPMWs) 
Characteristics of FPMWs are shown in Table 3. The day of emergence of the DF, SF1 
and SF2, and the day of selection were not different among the 3 age groups. Similarly, the 
diameter of the DF on the day of selection and the maximum pre-ovulatory diameter of the DF 
were not different between groups.  The SF1 was smaller at the time of selection. Both SF1 and 
SF2 reached a smaller maximum diameter in the ARA2 versus RA and ARA1 groups. No 
0.008 10.0b (10.0-12.0)8.0a,b (5.0-9.0)6.5a (5.0-8.3)Diameter of the LPDF on day of ovulation #1 (day 0) 
0.066 12.5 (9.5-16.0)20.0 (20.0-20.0)19.5 (16.5-22.8)
Diameter of the ovulatory follicle 
on LPMW day of emergence 
(mm) 
RA ARA1 ARA2 P-value 
n=10 n=3 n=10
Day of emergence (day)
DF -2.0a (-3.0--0.8) -2.0a,b (-2.0--2.0) -6.0b (-7.0--3.3) 0.049
SF1 -1.0 (-2.0-0.3) 2.0 (2.0-2.0) -1.5 (-6.0--0.3) 0.255 
SF2 -1.0 (-3.0--0.8) -1.0 (-4.0--0.8) 0.728 
Day of Selection 2.0 (0.5-4.5) 3.0 (2.0-4.0) 0.0 (0.0-2.0) 0.180
Diameter on day of Selection (mm)
DF 9.0 (6.5-11.0) 10.5 (10.0-11.0) 9.7 (8.0-10.0) 0.631
SF1 8.0 (7.5-9.5) 7.5 (7.0-8.0) 7.0 (5.0-9.0) 0.442
SF2 7.0 (6.0-7.8) 6.0 (6.0-6.0) 5.0 (4.0-6.5) 0.129
Maximum Diameter (mm)
DF 11.0a (10.0-12.0) 11.0a,b (11.0-12.0) 24.0b (13.0-27.0) 0.032
SF1 8.0 (7.8-10.0) 7.5 (7.0-8.0) 7.0 (5.3-9.0) 0.248
SF2 7.5a (7.0-9.0) 7.0a,b (7.0-7.0) 6.0b(4.0-6.0) 0.013
Growth interval of DF (days) 5.5a (4.8-8.3) 3.0a,b(2.0-4.0) 11.0b(8.0-15.0) 0.005
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obvious differences in the growth interval of the DF in FPMWs were detected between age 
groups.  
 The incidence of CFs within the FPMW was not different between age groups 
(P>0.050). In contrast, the incidence of ovulatory co-dominant follicles in the FPMW (i.e., 
polyovulation) tended to be higher in ARA2 (3/21, 14%) versus RA (0/27, 0%) group (P=0.070).  
 
Table 5.4 Characteristics of Follicular Phase Major Waves 
 
 
 
 
 
 
a,b,c Within rows, values with different superscripts are different. Day 0 = day of first ovulation. 
 
5.4.3 AFC 
 Changes in the distribution of AFC (2-9 mm and >6 mm averaged over the entire IOI) 
with age and in women with versus without LPMWs are shown in Figures 4 and 5, respectively.  
A decrease in mean AFC 2-9 mm occurred with age (P<0.001; Figure 5.4).  Similar decreases in 
mean AFC >4, >5, and >6 mm over the entire IOI were observed with age (P <0.001). Women in 
the RA group with LPMWs had a higher mean AFC >5 mm and >6 mm (18.5, 9.2) compared to 
RA ARA1 ARA2 P-value 
n=27 n=10 n=21
Day of emergence (day)
DF 13.0 (11.0-15.0) 15.0 (10.0-19.0) 13.5 (12.0-16.3) 0.708 
SF1 14.5 (11.8-16.0) 14.0 (9.0-17.0) 15.0 (13.5-19.0) 0.216
SF2 14.0 (11.0-16.0) 15.0 (11.0-20.0) 15.0 (14.8-19.3) 0.134
Day of Selection 19.0 (16.8-21.8) 18.0 (17.0-20.3) 19.0 (16.8-21.3) 0.927
Diameter on day of Selection (mm)
DF 10.1 (8.0-11.5) 9.2 (7.8-10.3) 10.1 (6.5-14.0) 0.723
SF1 9.0a (8.0-10.3) 9.0a (8.8-9.0) 7.0b (5.8-8.0) <0.001
SF2 8.0 (6.8-9.0) 7.0 (5.3-8.0) 6.0 (4.8-8.3) 0.157
Maximum Diameter (mm)
DF 21.0 (19.0-21.0) 19.0 (16.0-21.3) 20.0 (17.3-21.8) 0.400
SF1 9.0a (8.0-10.5) 9.0a (9.0-9.0) 7.0b (5.0-8.0) <0.001
SF2 9.0a (8.0-10.0) 8.0a (7.0-8.3) 7.0b (5.0-8.0) 0.001
Growth interval of DF (days) 12.5 (12.0-15.0) 11.0 (10.0-14.0) 12.0 (11.3-13.0) 0.050
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those without LPMWs (13.5, 5.5); (P=0.015, 0.025; Figure 5.5). A similar trend was detected for 
AFC 2-9 mm (P=0.079).  No differences were detected in the mean AFC 2-9, >4, >5, and >6 mm 
among women with versus without LPMWs in the ARA1 and ARA2 groups (P>0.050).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 Mean AFC in RA, ARA1, ARA2 groups over the entire IOI.  
º,* Indicate outliers. Across groups, values with no common superscripts within each graph are 
different (P<0.001). 
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Figure 5.5 Mean AFC over the entire IOI in women among the RA, ARA1, and ARA2 groups 
with versus without LPMWs. 
º Indicates outliers. 
 
5.5 Discussion 
 Our results supported the hypothesis that major waves of follicle development occur in 
women approaching and/or during the MT. The incidence of both luteal phase and follicular 
phase major waves was not different in women of reproductive age compared to those 
undergoing the transition to menopause. The dynamics of luteal phase major waves did change 
in women during the transition to menopause. Luteal phase major waves emerged earlier, grew 
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longer, and to a larger diameter in women in the ARA2 versus RA and ARA1 groups. In the RA 
and ARA1 groups, all LPMWs were anovulatory.  In contrast, in the ARA2 group, LPMWs were 
either ovulatory or anovulatory. Polyovulations and smaller subordinate follicles in the FPMW 
were detected in the ARA2, but not RA and ARA1 groups.   
5.5.1 Cycle Length 
 Our finding that the  IOI and FP lengths were not different across age groups,  contrasts 
with changes in menstrual cyclicity that have been previously associated with the MT in women 
(122), domestic farm animals (211), and non-human primates (249, 250). However, we did 
observe within-group variability in IOI and FP length with age. An abnormally long follicular 
phase in women of advanced reproductive age in our study was the consequence of lag phases, 
consistent with previous endocrine studies (10, 155). An abnormally short IOI was detected in 
one participant in our study. The shortened IOI resulted from the development of an ovulatory 
LPMW after which a follicular phase wave did not emerge. Documentation of an ovulatory 
LPMW in women with shortened cycles supports previous reports of ovulatory Luteal out of 
Phase (LOOP) endocrine events (10). Our finding that LP length did not change across age 
groups is supported by previous studies which report no change in luteal phase length across age 
groups in women (10, 168, 189, 192, 262) and domestic farm animals (210, 211). Decreased 
luteal function (i.e., production of  Progesterone (5, 6) and inhibin A (173) is one of the final 
changes detected in women undergoing the transition to menopause occurring in association with 
an increased incidence of anovulation (6, 202) and increased cycle length (5, 6, 155). We 
attribute the lack of changes in the length of the IOI, FP, and LP in our study to recruiting by age 
group versus STRAW stage and therefore including women at different stages of the MT.  
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5.5.2 Luteal Phase Major Waves 
 The prevalence of LPMWs in our study ranged from 30-50% across age groups, similar 
to previous reports of follicular waves in women (70, 263). Interestingly, the frequency of 
LPMWs did not differ with age. However, the growth dynamics of the LPMWs were markedly 
different in the older women.  In reproductive age women,  a major or minor wave of follicle 
development has been shown to emerge at the time of ovulation in association with the 
preovulatory rise in FSH (263). In the present study, women in the RA and ARA1 groups 
exhibited emergence of a LPMW at the time of ovulation, the dominant follicle grew to a median 
diameter of 11.0mm and then regressed in the early-mid luteal phase. However, in the ARA2 
group, LPMWs emerged earlier (i.e., in the mid-late follicular phase of the preceding IOI) and 
grew to large, often cystic diameters (range: 10.0-37.0 mm). It appeared that the LPMW in the 
ARA2 group may have emerged from a minor follicular phase wave preceding the first ovulation 
of the IOI. The largest follicle(s) of the LPMW had already achieved dominance at the time of 
the pre-ovulatory gonadotropin surge. Therefore, we postulate that the largest 1 or 2 follicles 
recruited into the LPMW responded to the preovulatory LH surge, which resulted in their 
continued growth during the luteal phase. 
 Although the LPMW growth dynamics in ARA1 women (aged 36-44) were not different 
compared to the RA and ARA2 groups, visual inspection of the data suggests the differences 
between ARA1 and ARA2 were not detectable due to a very small sample size in the ARAR1 
group (n=3). In ARA1 women, the LPMW day of emergence, the growth interval and maximum 
diameter of the DF very similar to the RA group. 
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 Follicle waves in the luteal phase of the menstrual cycle in reproductive age women have 
not been shown to ovulate (70, 263).  However, in the present study, we documented ovulation 
of a dominant follicle from a LPMW during the MT. This novel finding supports the notion that 
functional (i.e., FSH responsive, estrogenic) dominant follicles can grow in the luteal phase (76).  
Furthermore, growth and ovulation of LPMW dominant follicles supports previous reports of 
successful oocyte retrieval from follicles in the luteal phase in women undergoing ovarian 
stimulation for the treatment of infertility (109, 264). Further, documenting ovulation of LPMWs 
during menses has clinical implications for understanding contraceptive needs of women as they 
age.  
5.5.3 Follicular Phase Major Waves  
 Follicular phase major waves occurred in all but one woman in our study.  In general, the 
growth dynamics of FPMWs were conserved across age groups. The day of emergence, day of 
selection, and diameter of the dominant follicle at selection within FPMWs did not change across 
age groups. No obvious differences in growth interval were detected between age groups. Our 
findings are not consistent with reports of  earlier emergence of the ovulatory follicle (153, 193, 
194), earlier ovulation (193) or slowed preovulatory growth (194) in older women. We attribute 
differences in findings between our study and others in part to inconsistencies in methods used to 
evaluate follicle dynamics. In the present study, serial changes in individually identified follicles 
were quantified over an entire IOI. In contrast, previous studies involved endocrine endpoints as 
an indirect measure of follicle development and/or limited assessment of dominant follicle 
growth. Furthermore, differences in data categorization (i.e., age versus cyclicity) may have lead 
to differential findings between studies. Lag phases have been observed endocrinologically 
during the late MT (10, 155). However, follicular growth during lag phases had not been 
 60 
previously evaluated. We observed a prolonged phase of no follicle growth > 6mm prior to the 
development of the FPMW in 2 women in the ARA2 group. Antral follicles 2-5 mm represent 
the cohort of follicles available for recruitment (also referred to as ‘wave emergence’) (58). The 
absence of follicle growth >6 mm during the lag phase demonstrates the inability to develop 
major follicle waves.  
 The diameter of SF1 was smaller on the day of selection and the maximum diameter of 
SF1 and SF2 were smaller in the ARA2 versus ARA1 and RA. These findings are consistent 
with previous research in mares (211). In 5/20 cases in the ARA2 group, emergence and 
selection of the DF at 4-5 mm occurred on the same day because SF1 had already reached its 
peak diameter before regressing on the day of wave emergence. We believe smaller subordinate 
follicle peak diameters reflect the reduced number of recruitable follicles available at the time of 
wave emergence, attributed to the decreased ovarian reserve.  
 Documentation of codominance and increased incidence of polyovulation in the FPMW 
supports earlier reports of increased twinning rates with age in women (196) and domestic farm 
animals (211). The increased incidence on polyovulation as women approach menopause is 
thought to occur due to the elevated FSH (or ’widened FSH window’) during wave emergence of 
the FPMW during the MT, which allows more than one follicle to escape atresia and become 
dominant (74, 196, 265). 
5.4 AFC 
 A progressive decrease in AFC occurred in all age groups in the present study, as has 
been previously well-documented (162, 164, 175, 204). In the RA group, women with LPMWs 
had a greater AFC >6 mm compared to those without LPMWs. It appears that a greater ovarian 
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reserve may increase the likelihood of LPMWs in young women, but not those in the MT. 
Previous investigators have also proposed that a threshold for ovarian reserve exists, below 
which dysregulation and atypical hormone fluctuations causes aberrant follicle growth dynamics 
(10, 266).  
5.5.5 Limitations and Future Directions 
The inability to collect ultrasonographic data every day was one of the biggest challenges 
in our study, as it may have led to error in determining the timing of emergence of follicles 
within a wave. However, a scanning frequency of more than 1-3 days for a period of 6 weeks 
would not be considered practical or ethical by research volunteers and/or investigators. 
Collection of serial ultrasonographic data from 71 women in our study was conducted over a 5 
year period.  Even with a large sample size, there were relatively small sample sizes on a given 
day of the cycle within each of the 3 different age groups. Evaluation of changes in the number 
and growth dynamics of follicles <4 mm involves much more error compared to follicles >4 mm, 
especially when clear images of the ovaries cannot be obtained.  Future research should 
incorporate 3D ultrasonographic and/or high-resolution technologies for improved imaging of 
ovarian follicular dynamics in women.   
 Recently, criteria have been developed to characterize the physiologic stages of 
reproductive aging, originating from the Stages of Reproductive Aging Workshops (STRAW) 
(122, 267). The objectives of the staging systems are to provide standardized criteria for the 
clinical and scientific evaluation of reproductive aging in women. The STRAW criteria are based 
on changes in menstrual cyclicity, hormone production and antral follicle count (i.e., AFC) that 
occur in women throughout the reproductive lifespan (122). According to STRAW, the first 
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indication of reproductive aging is a change in menstrual cyclicity (122). We grouped our 
participants into STRAW categories of reproductive aging; however, the resulting limited sample 
size did not provide statistical power to test our hypotheses. Studies of this nature require 
significant financial resources and time commitments from both participants and investigators.   
 The findings from the present investigation have included the morphologic (i.e., growth) 
aspects of follicular dynamics as women age.  No functional (i.e., endocrinologic) data have been 
presented. We felt that inclusion of endocrine data was beyond the scope of the present 
manuscript. We have completed corresponding endocrine evaluations for a subset of women that 
participated in our study. The endocrine data will be published as a separate manuscript (Chapter 
6). Atypical and acute elevations in luteal phase estradiol (termed ‘LOOP’ events) have been 
reported in approximately 40% of women during the MT (10). The origins of the atypical luteal 
phase elevations, however, are not known. It is speculated that the development of luteal phase 
major waves may underlie the atypical elevations in luteal phase estradiol as women age. Insight 
into the origins of atypical estrogen production during the MT has important clinical implications 
for understanding the causes of vasomotor symptoms and estrogen-mediated risks of 
reproductive malignancies (201). Future research in this area will enable the development of safe 
and effective therapies for treating unwanted symptoms that will ultimately improve the quality 
of life of women as they age.  
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5.5.6 Summary 
 Major follicular waves developed during the follicular and/or luteal phases of ovulatory 
menstrual cycles during the transition to menopause.  The prevalence of major waves in the 
follicular and luteal phases was not different in reproductive age women compared to those of 
advanced reproductive age.  Luteal phase major waves emerged earlier, grew longer, and to a 
larger diameter as women progressed through the menopause transition. An increased incidence 
of polyovulation and smaller subordinate follicles were detected in FPMWs of women of 
advanced reproductive age. Lag phases were detected only in women of the ARA2 group.  These 
novel findings may provide insight into the origins of erratic and unpredictable changes in 
ovarian hormone production and associated unwanted symptoms (e.g., vasomotor symptoms) 
and risks of reproductive malignancies that women experience as they approach menopause.   
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Chapter 6 
 
 Age-Related Changes in Major Ovarian Follicular Wave Dynamics:  
Endocrinologic Characteristics  
 
Vanden Brink H1, Chizen D1, Robertson D2, Hale GE3, Burger H2, Baerwald A1 
 
1Department of Obstetrics, Gynecology & Reproductive Sciences, College of Medicine, 
University of Saskatchewan, Saskatchewan, Canada 
2Prince Henry’s Institute of Medical Research, Monash Medical Centre, Victoria, Australia 
3Department of Obstetrics and Gynecology, University of Sydney, New South Wales, Australia 
6.1 Abstract 
Context: Acute and atypical elevations in luteal phase estradiol secretion (i.e. >245pg/mL) have 
been reported in ovulatory women during the MT. However, the origins of the profound changes 
in estradiol production are not known.  
Objective: To test the hypothesis that profound and acute changes in hormone production during 
the MT are associated with the development of major follicular waves. 
Materials and Methods: A prospective, observational study was conducted in women of 
Reproductive Age (RA; 18-35 years; n=10) and Advanced Reproductive Age-2 (ARA2; 45-55 
years; n=17). The numbers and diameters of all follicles >2 mm were determined 
ultrasonographically every 2-3 days for 1 interovulatory interval (IOI). Blood samples were 
collected at each visit, and serum was assayed for FSH, LH, estradiol, inhibin A and B, AMH 
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and progesterone concentrations. Follicle wave dynamics and hormone production over the IOI 
were characterized and compared between age groups (SPSS v19.0, α=0.05). 
Results: In the ARA2 group, LPMWs developed in association with atypical elevations in 
estradiol concentrations in 4/8 women (50%). In the RA group, 5/10 women developed LPMWs 
in association with high, but not atypical, estradiol. In both RA and ARA2 groups, luteal 
estradiol was higher in women with (139.1, 177.8 pg/mL) versus without (78.0, 95.0 ng/mL) 
LPMWs (P=0.016, 0.074). Max diameter of the LPMW dominant follicle positively correlated 
with luteal phase estradiol (r=0.71, P<0.01) and negatively correlated with max luteal phase LH 
(r=-.52, P<0.05) when both age groups were combined. Max diameter of the LPMW dominant 
follicle was negatively correlated with mean luteal phase progesterone in the ARA2 group (r=-
.78, P<0.05). In the ARA2, but not RA group, progesterone was lower in women with (9.65 
ng/mL) versus without (13.0 ng/mL, P=0.027) LPMWs.  
Conclusions: The development of LPMWs during the MT is associated with acute and atypical 
elevations in estradiol in association with decreased luteal progesterone production.  
Keywords: Aging - Ovarian follicle - Menstrual cycle - Ovary - Estradiol 
 
6.2 Introduction 
 
 
 The Menopause Transition (MT) is a time of profound changes in reproductive 
physiology (150, 231).  The MT begins at the age of 45-47, lasts approximately 4-7 years, and 
leads up to menopause which occurs at an average age of 51 years (77, 149, 150). Changes in 
menstrual cyclicity are the first clinical signs of entry into the MT (122). A shortening of the 
menstrual cycle usually occurs in the early MT (122, 151-153). As the MT progresses, increased 
cycle length variability and eventual lengthening of the menstrual cycle occurs due to an 
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increasing incidence of delayed ovulation and anovulatory cycles (6, 122, 150, 154-158). The 
ovarian origins of age-related changes in menstrual cyclicity are not fully understood.  
 Reproductive aging occurs as a result of the depletion of the ovarian reserve (77, 149, 
160, 162). A reduction in the number of primordial follicles comprising the ovarian reserve leads 
to a decrease in in the antral follicle count (AFC) and a correspondent decrease in serum AMH 
and inhibin B production. AMH is produced by granulosa cells of pre-antral and early antral 
follicles up to 8-10mm (48, 54), while inhibin B is produced from all antral follicles of the 
recruited ‘cohort’ or ‘wave’ (i.e., 2-12mm)(48). The loss of negative feedback of inhibin B on 
FSH with age results in an overall rise in serum FSH (162, 168, 172, 195). The fall in AMH and 
inhibin B and corresponding rise in FSH are the first endocrine changes that occur during 
reproductive aging (122). 
Inhibin A is produced by the dominant follicle in the mid-follicular phase and the CL in 
the luteal phase (50, 51). Serum concentrations of inhibin A decrease towards the later stages of 
the MT in association with an increased incidence of lag phases (i.e., periods of no follicular 
estrogen production), anovulation, and cycle length variability (168, 172, 173, 256, 268).  
A gradual increase in estrogen occurs early in the MT (i.e., up until 2 years prior to 
menses) followed by a marked decline as women enter the late MT and menopause (7, 228, 269). 
The fall in estrogen is one of the last hormonal changes to precede menopause, in association 
with increased cycle length, reduced luteal progesterone and elevated gonadotropins (6, 155, 
188, 229). Contrary to the notion of a gradual rise and fall in estrogen, great inter-cycle and intra-
/ inter-woman variability in follicular and luteal phase estrogen secretion has been documented 
during the MT (6, 10, 182). Elevated follicular phase estrogen has been associated with the 
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growth of multiple dominant follicles (193, 194) and dysregulation of FSH production (169). 
Low follicular phase estrogen has been associated with lag phases and anovulatory cycles (1, 6, 
10). Acute and atypically high luteal phase estrogen has been described in association with either 
normal progesterone, or decreased luteal progesterone and lower luteal LH (1, 6, 10, 151, 182). 
In a recent study, Luteal-Out-Of-Phase (LOOP) events were detected as a rise in estrogen which 
began in the mid-luteal phase and persisted into the early follicular phase in association with 
decreased luteal progesterone (10). The LOOP events (defined as estrogen concentrations outside 
the normal luteal phase reference range or >900pmol/L) occurred in approximately 40% of 
women during the MT (10). An LH surge (interpreted to represent ovulation) was detected in the 
early follicular phase in 3/6 (50%) women with a LOOP event (10). The origins of the atypical 
luteal phase estradiol are not known. However, it has been speculated that major waves of antral 
follicle development underlie the atypical estradiol fluctuations (10).  
 We have previously documented 2-3 waves of antral folliculogenesis during the 
menstrual cycle in reproductive age women (70, 107). Major waves were defined as those in 
which selection of a dominant follicle occurred from a recruited cohort of antral follicles >5mm 
(33). Minor waves were those in which dominance did not occur (33). Similarly, we have 
recently documented that more than one major follicle wave may develop during a given cycle in 
women during the MT (270). The incidence of major waves in the follicular and luteal phases 
was similar in reproductive versus advanced reproductive aged women. Polyovulation and 
smaller subordinate follicles were detected in the Follicular Phase Major Waves (FPMWs) in 
women of advanced reproductive age (>45 years old). The FPMW day of emergence, selection, 
and diameters at selection and ovulation of the dominant follicle were similar across age groups. 
However, in advanced reproductive age women, Luteal Phase Major Waves (LPMWs) emerged 
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earlier (i.e., prior to ovulation) compared to reproductive age women (i.e., at the time of 
ovulation). In advanced reproductive aged women the largest follicle of the LPMW had already 
achieved dominance at the time of ovulation and then continued to grow in the luteal phase. The 
dominant follicle of the LPMW grew for a longer period of time (11 versus 6 days) and to a 
larger diameter (24 versus 11 mm) during the MT compared to women of reproductive age. Most 
(9/10) LPMWs during the MT were anovulatory. However, in one case, a LPMW resulted in 
ovulation at the time of menses. Reproductive age women with LPMWs had a higher AFC >6 
mm compared to those without LPMWs. However, no effect of AFC on the development of 
LPMWs was detected during the MT. 
  The physiologic origins of acute and atypical elevations in luteal phase estrogen 
production during the MT are not known. It is plausible that these profound alterations in 
hormone production during the MT may originate from the emergence of major follicle waves. 
Associations between age-related changes in hormone production and follicle wave dynamics 
have not been investigated. The objective of the present study was to characterize the endocrine 
changes that occurred in association with major follicular wave dynamics as women age. Our 
general hypothesis was that changes in major follicular wave dynamics would underlie changes 
in hormone production as women approached menopause. The following specific hypotheses 
were tested: 
1. Follicular Phase Major Waves Elevated serum estradiol and inhibin A would be detected 
in advanced reproductive versus reproductive-aged women, in association with a greater 
incidence of codominance and/or polyovulation;  
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2. Luteal Phase Major Waves Atypically high estradiol and inhibin A secretion as well as 
decreased progesterone production would be associated with the development of LPMWs in 
women of advanced reproductive age; and, 
3. Major Waves and Markers of Ovarian Reserve Greater luteal phase inhibin B and AMH 
concentrations would be detected in women with versus without LPMWs, irrespective of age. 
6.3 Materials and Methods 
 A prospective, observational study was conducted from 2006-2011.  The morphologic 
(i.e., ultrasonographic) aspects of this study have been described in detail elsewhere (270). The 
study protocol was approved by the Biomedical Research Ethics Board at the University of 
Saskatchewan and the Strategic Priorities and Planning Committee of the Saskatoon Health 
Region.  Study procedures were conducted in accordance with the Tri-Council Policy Statement 
on the Ethical Conduct for Research Involving Humans. 
6.3.1 Study Participants 
 Participants were recruited using electronic and paper advertisements posted throughout 
the Saskatoon Health Region, University of Saskatchewan, and Women’s Midlife Health Centre 
of Saskatchewan. Thirty women  (n=30) were enrolled in this study as a subset of a previous 
study to characterize age-related changes in follicular wave dynamics (270). Data from 3/30 
women were excluded for the following reasons: incomplete IOI during the study period (n=1) or 
the development of anovulatory cycles (n=2). Data from the remaining 27 participants were 
included in our analyses. Women were divided into the following age categories: 1) 
Reproductive Age (RA; 18-35 years, n=10); and, 2) Advanced Reproductive Age 2 (ARA2; 45-
55 years, n=17). The RA age group was chosen to represent a reference group of ovulatory 
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women in the peak reproductive stage of life. The ARA2 age group was chosen to represent 
ovulatory women undergoing the transition to menopause. The Advanced Reproductive Age 1 
group represented women during the late reproductive stage of life (36-44 years of age). Women 
in the ARA1 group were evaluated in a previous study (270) to characterize age-related changes 
in follicle wave dynamics; however, women in the ARA1 group were not evaluated in the 
present study. Informed consent was obtained by all participants before study procedures were 
initiated. Diary cards were completed by participants to record adverse events or medications 
taken during the study.   
 Inclusion criteria included a normal serum complete blood count, serum TSH, prolactin, 
and ßhCG. Women aged 18-35 were eligible if they had a history of regular menstrual cycles 
(i.e., 21-45 days long). However, women aged 45-55 were eligible if they had no more than 12 
months of amenorrhea. Exclusion criteria included the use of any type of hormone therapy 
within 3 months of study participation, current smokers, documented ovarian failure, infertility 
of unexplained or female origin, medical conditions known or suspected to interfere with 
reproductive function, presence of only one ovary, ovaries which we were unable to visualize 
ultrasonographically, use of any medications known or suspected to interfere with reproductive 
function, pregnancy or lactation, and/or participation in an investigational drug trial within 30 
days of study participation.  
6.3.2 Study Procedures 
 Transvaginal ultrasonography was conducted to evaluate ovarian and uterine function in 
each participant (6-9MHz curvilinear array transducer, Ultrasonix RP Burnaby, BC, Canada).  
Ultrasound exams were performed by 1 of 2 investigators (ARB, HKV). Scans were initiated in 
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the early-mid follicular phase (i.e., day 8-15) and continued every Monday, Wednesday, and 
Friday for one complete interovulatory interval (IOI). An IOI was defined as the interval from 
one ovulation to the subsequent ovulation. When a preovulatory follicle was detected at 14-
16mm, ultrasound examinations were performed daily in order to determine the day of ovulation. 
Ovulation was defined as the disappearance of a dominant follicle seen on the previous day and 
subsequent visualization of the Corpus Luteum (CL), followed by a rise in serum progesterone to 
at least 5.0 ng/mL (10, 107, 258). Anovulation was defined as the development of a dominant 
follicle which failed to ovulate determined by ultrasonographic visualization of ovulatory failure 
and a serum progesterone concentration of <5.0 ng/mL.  
 During each examination, video clips of each ovary in both the sagittal and transverse 
planes were recorded. All video clips were reviewed retrospectively by single investigator 
(HKV) using customized imaging software (Santesoft DICOM Editor Version 3.1.0). The 
number of follicles >2mm and the diameter of all follicles >4mm were tabulated at each visit for 
each participant. Measurements were taken separately for the right and left ovaries. Follicle 
diameter measurements were made when the longest and widest follicle dimensions were 
observed. The mean diameter of each follicle < 10 mm was calculated as the average of the 
length and width. When a follicle achieved a mean diameter of >10 mm in one plane, the same 
follicle was identified in the other plane, and the length and width measurements were made 
again. Thus, the overall mean diameter of follicles >10mm was calculated as the mean of the 
average diameter measurements in the sagittal and transverse planes. Serial changes in follicle 
diameter during the IOI were tabulated using the ID method. Briefly, the ID method involved 
sketching all follicles >4mm in each ovary (70, 259, 260).  The day-to-day identities of all 
individual follicles which grew to >7mm during the IOI were retrospectively identified and 
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growth profiles were graphed for each participant in Windows Office Excel (2003). The numbers 
of follicles (i.e., AFC) across the entire IOI were reported for each participant for the following 
size categories: 2-5 mm, 2-9 mm, 2-10 mm, >4 mm, >5 mm, and >6 mm. 
 Blood samples were drawn at each study visit. Approximately 5.0mL of blood was 
collected into a 10 ml clot activated tube and allowed to sit at room temperature for 30-60 
minutes before centrifugation for 20 minutes at 2500 rpm. The serum was drawn off and stored 
at -50 degrees Celsius. 
  After study completion, serum samples were transported to the Prairie Diagnostics 
Services Laboratory at the University of Saskatchewan for analyses. Solid-phase two-site 
chemiluminescent immunometric assays (Immulite; Siemens Healthcare Diagnostics Ltd.,United 
Kingdom) were performed to measure concentrations of FSH and LH. Double antibody 
radioimmunoassays (Count-A-Coat, Siemens Healthcare Diagnostics Inc., Los Angeles, CA, US) 
were performed to measure concentrations of estradiol. Solid-phase radioimmunoassays (Count-
A-Coat, Siemens Medical Solutions Diagnostics) were performed to measure concentrations of 
progesterone. Enzyme-linked immunosorbent assays (Beckman Coulter Inc., Brea, CA, USA) 
were performed to measure inhibin A, inhibin B, and AMH. FSH and LH assays were performed 
in singlicate. Inhibin A, inhibin B, estradiol, progesterone, and AMH assays were performed in 
duplicate. Inter-assay coefficients of variation were as follows: inhibin A (low = 14.4%, high 
7.8%), inhibin B (low = 6.02%, high = 7.34%), AMH (low = 7.81%, high = 10.5%), FSH (low = 
5.8%, med = 5.8%, high = 6.7%), LH (low = 5.7%, med = 5.3%, high = 3.4%), progesterone 
(low = 17.1%, med = 9.5%, high 15.2%), estradiol (low = 23.2%, high = 12.9%). Intra-assay 
coefficients of variation were as follows: inhibin A (5.5%), inhibin B (5.7%), AMH (5.7%), 
progesterone (low = 6.3%, med = 3.8%, high = 13.0%), estradiol (low = 15.5%, high = 9.9%). 
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The levels of detection of the assays were 5.0 pg/mL for inhibin A, 2.6 pg/mL for inhibin B, 
0.08ng/mL for AMH, 1.4 pg/mL for estradiol, 0.02 ng/mL for progesterone, 0.1mIU/mL for LH 
and FSH. 
6.3.3 Definitions 
 Major follicular waves were characterized by evaluating changes in both the number and 
growth dynamics of individual follicles. A major follicle wave was defined as an increase 
followed by a decrease in the total number of follicles >6mm, occurring in association with the 
emergence of at least one dominant follicle as previously described (33, 270).  
 The day of wave emergence was defined as the day that the dominant follicle was 
identified retrospectively at 4-5mm. A Dominant Follicle (DF) was defined as a follicle which 
grew to a diameter of >10mm and exceeded the next largest follicle by at least 2mm. A 
Codominant follicle (CF) emerged from the same wave as the DF, attained a diameter of 
>10mm, and exceed the next largest follicle by >2mm. Subordinate follicles were those follicles 
in a wave that did not achieve dominance.  
 Atypically high estradiol was defined as either luteal phase estradiol >200 pg/mL and/or 
a secondary rise in estradiol not associated with luteal phase progesterone. This definition is 
based on the expected range in serum estradiol concentration during the luteal phase and 
previous characterization of atypically high estradiol (10, 271). 
6.3.4 Statistical Analyses 
 Standardized graphs for the following endpoints over the IOI were created for each 
participant: 1) follicle diameter, using the ID method; 2) AFC 2-5 mm, 2-9 mm, 2-10 mm, >4 
mm, >5 mm, and >6 mm; and 3) serum concentrations of FSH, LH, estradiol, progesterone, 
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inhibin A, inhibin B, and AMH. Graphs were centralized to the day of the first ovulation. 
Normality was evaluated for each study endpoint using Shapiro Wilk tests (SPSS Version 19.0, 
2010). Mann-Whitney U-tests were conducted to compare study endpoints between age groups 
(SPSS Version 19.0, 2010). Endocrine concentrations were compared in women with and 
without cases of codominance (i.e., ovulatory and/or anovulatory). The incidence of FPMWs and 
LPMWs were compared between groups using Fisher’s Exact tests (SPSS Version 19.0, 2010). 
Continuous data are reported as median (interquartile range). Categorical data are reported as 
percentage of age group (proportion of group). Bivariate correlations between endocrine and 
follicular endpoints were conducted using the Pearson or Spearman coefficient as appropriate 
(SPSS Version 19.0, 2010).  
6.4 Results  
6.4.1 Participant Demographics  
Participant demographics and cycle phase lengths of the RA group and ARA2 group are 
presented in Table 6.1. As expected, age, gravidity and parity increased with age. Body mass 
index and prevalence of smoking were similar among groups. The length of the IOI, follicular 
phase, and luteal phase did not differ in the RA versus ARA2 groups (Table 6.1; P>0.05). 
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Table 6.1 Participant Demographics and Cycle Characteristics Compared Between Age Groups 
 
 
 
 
 
 
Day 0 = day of first ovulation of the IOI. 
 
6.4.2 Luteal Phase Major Waves 
 The prevalence of LPMWs between age groups was not different (RA: 50%; ARA2: 
47%; P=0.600).   
The growth profiles and corresponding hormone profiles of individual participants with and 
without LPMWs in the RA (Figure 6.1) and ARA2 (Figure 6.2) groups are shown. In Figure 6.1 
(Example A, RA) and Figure 6.2 (Example A, ARA2), no LPMWs were observed. Luteal phase 
estradiol remained within normal ranges in association with a normal luteal phase rise and fall in 
progesterone. In Figure 6.1 (Example B, RA), a LPMW emerged at the time of ovulation in 
association with the preovulatory rise and fall in FSH and LH.  Immediately thereafter, estradiol, 
inhibin A, and progesterone began to rise. Luteal phase estradiol and progesterone remained 
within normal ranges. In Figure 6.2 (Examples B-D, ARA2), LPMWs emerged prior to ovulation 
in the mid follicular phase. The largest follicles of the LPMWs had already become dominant 
(i.e., > 10 mm) at the time of ovulation and continued to grow following the preovulatory LH 
RA ARA2 P-value
n=10 n=17
Demographics
Age (years) 27.0 (21.8-34.3) 48.0 (46.0-49.5) 0.000
BMI (kg/m2) 26.5 (24.8-29.8) 25.6 (22.8-27.4) 0.238
Gravidity (#) 0.0 (0.0-1.3) 3.0 (2.0-4.0) 0.002
Parity (#) 0.0 (0.0-0.3) 2.0 (2.0-3.0) 0.003
Ever-smoker (n) 0.0 2.0 0.516
Cycle Phase Lengths
IOI (days) 27.5 (25.0-30.0) 27.0 (25.5-29.5) 0.667
Follicular Phase Length (days) 14.5 (12.8-16.0) 13.0 (12.0-15.0) 0.333
Luteal Phase Length (days) 14.5 (12.3-15.0) 13.0 (13.0-15.0) 0.759
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and FSH surges. Codominance (i.e., the development of 2 dominant follicles) was observed in 
Examples B and C. In Figure 6.2 (Example B), inhibin B decreased during the early luteal phase. 
Two acute rises in estradiol were observed (> 200pg/mL). The first rise began 2 days before 
ovulation and peaked 12 days after ovulation in association with the growth of 2 LPMW 
dominant follicles. A smaller, secondary atypical rise in estradiol and inhibin A was observed 
between days 20-22 (corresponding to the early follicular phase) after one dominant follicle of 
the LPMW regressed but the other persisted. One dominant follicle of the LPMW regressed in 
the late luteal phase whereas the second dominant follicle persisted into the subsequent follicular 
phase. FSH was suppressed in the luteal phase in association with atypically high estradiol 
production. Progesterone concentrations were normal. In comparison, in Figure 6.2 (Example C), 
a single acute rise in estradiol began 1 day before ovulation and peaked 2 days after ovulation in 
association with the growth of 2 LPMW dominant follicles. Both dominant follicles persisted 
throughout the luteal phase in the presence of declining inhibin B, low progesterone and low 
inhibin A. In Figure 6.2 (Example D), a LPMW emerged 4 days before ovulation in association 
with an increase in FSH and subsequent increase in inhibin B. Estradiol rose and progesterone 
and inhibin A fell in association luteal regression and continued growth of the LPMW dominant 
follicle. The dominant follicle grew throughout the luteal phase in the presence of a normal rise 
and fall in progesterone and inhibin A. After luteal regression, the dominant follicle continued to 
grow and produce estradiol until it ovulated in the early follicular phase. A second rise in 
progesterone was detected in the early follicular phase.  
Endocrine characteristics in the luteal phase of women between age groups are compared 
in Table 6.2. Luteal phase FSH was greater while inhibin B and AMH concentrations were lower 
in ARA2 versus RA women (P<0.05). Progesterone was higher in ARA2 versus RA women 
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(Table 6.2; P<0.05). There were no differences in LH, estradiol, or inhibin A over the luteal 
phase between age groups (Table 6.2; P>0.05).  
Endocrine characteristics of women with versus without LPMWs in the 2 study groups 
are shown in Table 6.2. Within the RA group, luteal phase inhibin B and estradiol were higher in 
women with versus without LPMWs (Table 6.2; P=0.009 and 0.028). Similarly, in the ARA2 
group, max luteal phase estradiol tended to be higher in women with versus without LPMWs 
(Table 6.3; P=0.074). In both RA and ARA2 groups; the 75% quartile for max luteal phase 
estradiol was markedly higher in women with LPMWs versus without LPMWs (Table 6.2).  In 
contrast, luteal phase progesterone was lower (Table 6.2; P=0.012, respectively) in ARA2 
women with versus without LPMWs.  
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SI Conversion Factors: FSH and LH: mIU/mL x 1.0 = IU/L; Progesterone: ng/mL x 3.18 = 
nmol/L; Estradiol: pg/mL x 3.67 = pmol/L; Inhibin A and B: pg/mL x 1.0 = ng/L; AMH: ng/mL 
x 7.14 = pM 
Figure 6.1 A-B Growth profiles of the largest 3 follicles (determined using the ID Method) and 
corresponding hormone profiles during the IOI for individual participants in the RA group. The 
first day of menses is indicated by a dashed vertical line for each example (top row). ov= 
ovulation (top row). 0=day of 1st ovulation (x-axes for all graphs). Dominant follicles of the 
LPMW are indicated by open circles, and dominant follicles of the FPMW are indicated by 
closed circles on the follicle growth profiles (top row). The days that the CL was detected 
ultrasonographically are indicated by a solid bar on the x-axis. In Example A, follicle and 
endocrine profiles for a single woman without a LPMW are shown. In Example B, profiles for a 
single woman with a LPMW are shown. The IOI was 30 days in Example A and 25 days in 
Example B.   
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SI Conversion Factors: FSH and LH: mIU/mL x 1.0 = IU/L; Progesterone: ng/mL x 3.18 = 
nmol/L; Estradiol: pg/mL x 3.67 = pmol/L; Inhibin A and B: pg/mL x 1.0 = ng/L; AMH: ng/mL 
x 7.14 = pM 
 
Figure 6.2 A-D Examples of growth profiles of the largest 3 follicles (determined using the ID 
Method) and corresponding hormone profiles during the IOI for 4 participants in the ARA2 
group.  The first day of menses is indicated by a dashed vertical line for each example (top row). 
Ov=ovulation (top row). 0=day of 1st ovulation (x-axes for all graphs). Dominant follicles of the 
LPMW are indicated by open circles, and dominant follicles of the FPMW are indicated by 
closed circles on the follicle growth profiles (top row). The days that the CL was detected 
ultrasonographically are indicated by a solid bar on the x-axis. Follicle and endocrine profiles for 
a single woman without a LPMW are shown in Example A.  Profiles for a single woman with 2 
dominant follicles developing within an anovulatory LPMW are shown in Example B. A long 
IOI (40 days) was observed in Example B. Example C includes follicle and endocrine profiles 
for a second woman in whom 2 dominant follicles also developed within the anovulatory 
LPMW. In Example C, a short IOI (20 days) was observed. In Example D, the LPMW resulted 
in ovulation and a 17 day IOI. 
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Table 6.2 Endocrine Characteristics of Luteal Phase Major Waves  
 
 
 
 
 
 
 
 
 
 
 
 
 
SI Conversion Factors: FSH and LH: mIU/mL x 1.0 = IU/L; Progesterone: ng/mL x 3.18 = 
nmol/L; Estradiol: pg/mL x 3.67 = pmol/L; Inhibin A and B: pg/mL x 1.0 = ng/L; AMH: ng/mL 
x 7.14 = pM 
Data are reported over the luteal phase of the IOI. 
* Within rows, P-values represent comparisons between women with and without LPMWs. 
Ψ Within column 2, common endpoints between age groups are compared. a,bValues with 
different superscripts are different (P<0.05).  
Irrespective of LPMW 
DevelopmentΨ LPMW Detected* LPMW Not Detected* P-value*
RA n=10 n=5 n=5
Mean FSH (mIU/mL) 4.7 (3.0-5.7)a 4.7 (3.1-5.4) 4.8 (2.7-6.0) 0.917
Max FSH 7.4 (5.1-11.4) a 7.3 (5.6-11.8) 7.6 (5.6-11.8) 0.602
Mean LH (mIU/mL) 7.1 (5.6-10.5) 8.6 (6.5-16.1) 6.5 (6.5-16.1) 0.175
Max LH 16.4 (8.4-31.2) 18.3 (15.5-43.6) 8.69 (6.33-24.9) 0.117
Mean Inhibin B (pg/mL) 24.66 (17.94-50.05) a 48.7 (30.5-55.7) 19.1 (13.4-19.5) 0.009
Max Inhibin B 74.45 (42.8-145.2) a 125.9 (58.7-205.6) 49.3 (34.7-77.9) 0.117
Mean AMH (ng/mL) 2.35 (1.60-2.97) a 2.37 (2.00-4.43) 1.84 (1.11-2.66) 0.251
Max AMH 3.05 (1.87-3.80) a 3.60 (2.49-6.19) 2.31 (1.40-3.15) 0.076
Mean E2 (pg/mL) 73.25 (49.3-95.0) 90.46 (73.3-109.9) 53.3 (35.2-67.3) 0.028
Max E2 118.0 (72.9-140.0) 139.1 (119.5-166.6) 78.0 (56.1-105.7) 0.016
Mean Inhibin A (pg/mL) 38.0 (33.7-44.0) 37.2 (28.1-49.0) 38.9 (36.1-46.4) 0.347
Max Inhibin A 57.9 (49.4-81.0) 53.3 (35.9-93.2) 59.2 (54.1-81.4) 0.465
Mean Prog (ng/mL) 7.97 (6.01-10.05) a 9.36 (6.00-10.10) 6.70 (5.75-9.25) 0.602
Max Prog 12.92 (10.07-18.21) 14.98 (8.10-20.3) 11.10 (10.20-16.30 0.602
ARA2 n=17 n=8 n=9
Mean FSH (mIU/mL) 5.8 (4.5-8.1) b 6.6 (5.0-8.4) 5.2 (4.4-7.5) 0.211
Max FSH 10.60 (7.63-16.6) b 14.0 (8.7-17.3) 8.2 (7.3-14.4) 0.210
Mean LH (mIU/mL) 6.89 (5.41-8.84) 6.9 (6.1-7.9) 5.8 (4.7-9.4) 0.773
Max LH 13.4 (10.1-16.4) 13.3 (9.5-18.4) 14.8 (10.1-15.4) 0.962
Mean Inhibin B (pg/mL) 8.6 (3.0-20.9) b 16.0 (3.4-27.7) 7.1 (2.7-15.6) 0.277
Max Inhibin B 22.9 (4.6-64.5) b 39.8 (5.9-82.4) 22.9 (3.1-55.8) 0.573
Mean AMH (ng/mL) 0.10 (0.08-0.34) b 0.09 (0.08-0.11) 0.13 (0.08-0.89) 0.173
Max AMH 0.15 (0.08-0.45) b 0.12 (0.08-0.21) 0.15 (0.09-1.09) 0.262
Mean E2 (pg/mL) 73.5 (60.47-125.47) 96.9 (64.5-199.6) 71.1 (57.3-99.0) 0.321
Max E2 123.5 (91.4-249.9) 177.8 (105.6-327.0) 95.0 (86.2-144.7) 0.074
Mean Inhibin A (pg/mL) 42.8 (28.5-48.3) 39.4 (26.0-44.7) 45.3 (32.4-57.3) 0.178
Max Inhibin A 62.50 (41.55-87.90) 58.3 (34.3-71.6) 69.6 (51.1-100.0) 0.248
Mean Prog (ng/mL) 11.61 (8.13-13.05) b 9.65 (5.87-11.30) 13.0 (10.00-15.90) 0.027
Max Prog 19.30 (14.44-25.89) 16.0 (9.87-18.90) 24.5 (18.80-28.30) 0.012
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6.4.3 Follicular Phase Major Waves (FPMWs) 
The prevalence of FPMWs between age groups was not different (RA: 10/10, 100%; 
ARA2: 16/17; 94%; P=0.630). All FPMWs were ovulatory and all but 1 woman in the ARA2 
group had a FPMW during the IOI. Polyovulatory FPMWs occurred only in the ARA2 group 
(n=3/17). 
The growth profiles and corresponding hormone profiles of individual participants with 
and without FPMWs in the RA (Figure 6.1) and ARA2 (Figure 6.2) groups are shown. In Figure 
1 (Example A, RA), a FPMW with a codominant follicle was observed. One dominant follicle 
regressed, and the other continued to grow preferentially. FSH, inhibin B and AMH rose in 
association with wave emergence in Figure 6.1 (Example A and B, RA). A secondary rise in 
inhibin B was observed in the early follicular phase in Figure 6.1 (Example A and B; RA). 
Inhibin A and estradiol rose in association with the selection and continued growth of the 
dominant follicle. Progesterone remained low throughout the follicular phase.  
Wave emergence was more variable in women belonging to the ARA2 group. The range 
was from 3 days before to 8 days after the onset of menses. There was no FPMW in Figure 6.2 
(Example D) because the LPMW was ovulatory in the early follicular phase. LPMW dominant 
follicles persisted into the follicular phase in Examples B and C. In Figure 6.2 (Example B), 
FPMW emergence did not occur until the atypical estradiol secretion associated with the LPMW 
dominant follicles fell. FSH and inhibin B rose in association with wave emergence in Figure 6.2 
(Examples A-C, ARA2). Inhibin A and estradiol rose in association with dominant follicle 
growth in Figure 6.2 (Examples A-C). However, a break in sampling of one week may have 
impacted our ability to detect the estradiol rise in Figure 6.2 (Example B).  
 82 
Endocrine characteristics in the follicular phase of women between age groups are 
compared in Table 6.3. FSH was higher and inhibin B and AMH were lower in ARA2 versus RA 
women (Table 6.3; P<0.05). Follicular phase estradiol tended to be higher in the ARA2 versus 
RA groups, in association with a greater prevalence of polyovulation (Table 6.3, P-value versus 
adjusted P-value).  
Table 6.3 Endocrine Characteristics of Follicular Phase Major Waves  
 
 
 
 
 
 
 
 
 
 
SI Conversion Factors: FSH and LH: mIU/mL x 1.0 = IU/L; Estradiol: pg/mL x 3.67 = pmol/L; 
Inhibin A and B: pg/mL x 1.0 = ng/L; AMH: ng/mL x 7.14 = pM 
Data are reported over the follicular phase of the IOI. Unadjusted p-value reflects comparisons 
between groups in all (ovulatory) participants.*Adjusted p-value reflects comparisons after 
removal of polyovulatory cycles from the dataset.  
 
 
Inhibin A (pg/mL)
E2 (pg/mL)
AMH (ng/mL)
Inhibin B (pg/mL)
LH (mIU/mL)
FSH (mIU/mL)
RA ARA2 P-value (Adjusted)*
n=10 n=17
Mean 7.1 (4.8-8.5) 11.1 (7.4-13.1) 0.010 (0.019)
Max 10.2 (8.0-13.2) 19.3 (11.2-21.8) 0.025 (0.033)
Day 2-4 7.4 (4.3-7.9) 15.5 (450-19.4) 0.006 (0.016)
Mean 11.9 (7.0-18.6) 12.1 (7.2-13.8) 1.000 (0.953)
Max 30.1 (18.1-76.1) 36.0 (18.5-53.2) 0.880 (0.861)
Day 2-4 6.3 (4.2-9.6) 8.7 (6.2-12.0) 0.092 (0.074)
Mean 68.5 (61.9-79.9) 50.7 (31.2-74.5) 0.004 (0.001)
Max 101.0 (91.3-118.1) 77.2 (46.8-103.2) 0.027 (0.012)
Day 2-4 64.8 (49.2-73.8) 39.7 (2.6-67.3) 0.018 (0.030)
Mean 2.53 (1.78-3.11) 0.09 (0.08-0.20) (<0.001) (<0.001)
Max 3.04 (2.27-4.40) 0.12 (0.08-0.30) (<0.001) (<0.001)
Day 2-4 2.23 (1.99-2.38) 0.08 (0.08-0.37) (<0.001) (<0.001)
Mean 71.4 (60.5-80.5) 81.2 (63.6-132.9) 0.175 (0.292)
Max 164.8 (144.7-199.6) 225 (147.7-323.9) 0.098 (0.242)
Day 2-4 16.0 (9.6-26.1) 22.8 (15.23-36.52) 0.075 (0.084)
Mean 19.4 (14.8-21.1) 22.3 (15.3-27.4) 0.422 (0.482)
Max 50.9 (40.0-54.0) 47.3 (35.1-60.2) 0.802 (0.349)
Day 2-4 5.0 (5.0-7.4) 10.45 (5.0-12.75) 0.331 (0.213)
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6.4.4 Hormone Production and Diameter of the LPMW Dominant Follicle 
Bivariate correlations between max diameter of the dominant follicle in the LPMW and 
mean and maximum reproductive hormone concentrations of the luteal phase are reported in 
Table 6.4. In the RA group, the maximum diameter of the dominant follicle in the LPMW 
positively correlated with mean luteal phase estradiol and negatively correlated with maximum 
luteal phase LH (r=0.95, -0.95; P<0.01). In the ARA2 group, the maximum diameter of the 
dominant follicle in the LPMW correlated negatively with mean luteal phase progesterone (r=-
0.78, P<0.05). When age groups were combined, the maximum diameter of the dominant follicle 
in the LPMW correlated positively with luteal estradiol (mean: r=0.59, p<0.05; max: r=0.71, 
P<0.01) and negatively with maximum luteal LH (r=-0.52, P<0.05). The maximum diameter of 
the dominant follicle in the LPMW was not correlated with inhibin A across any of the age 
groups.  
6.4.5 Major Waves and Markers of Ovarian Reserve  
In RA women, the mean AFC >6mm and inhibin B over the IOI were greater in women 
with LPMWs versus those without (Figure 6.3; p=0.009).  In ARA2 women, no differences in 
AFC, AMH, or inhibin B were detected between women with and without LPMWs (Figure 6.3).  
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Table 6.4 Relationship between LPMW Dominant Follicle Diameter and Hormone 
Concentrations during the Luteal Phase 
 
 
 
 
 
 
 
* P<0.05; ** P<0.01; ***P<0.001; NS, not significant; T, trend (0.05> P <0.09). LPDF = luteal 
phase dominant follicle of the major wave. LP = luteal phase. Tests are one-tailed test. 
 
 
 
 
 
 
 
 
 
RA ARA2 All Women
n=5 n=8 n=13
Max LPDF diameter vs. 
Mean LP E2 .95 ** .38 NS .59 *
Max LP E2 .53 NS .49 NS .71**
Mean LP Prog .53 NS -.78 * -.25
Max LP Prog .53 NS -.61 T -.10
Mean LP LH -.74 T .16 NS -.13
Max LP LH -.95 ** -.18 NS -.52 *
Mean LP Inhibin A .00 NS -.27 NS .00
Max LP Inhibin A -.16 NS -.40 NS -.10
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SI Conversion Factors: Inhibin A and B: pg/mL x 1.0 = ng/L; AMH: ng/mL x 7.14 = pM 
Figure 6.3 A-C Differences in  mean AFC >6mm (A), inhibin B (B), and AMH (C) over the IOI 
in women with versus without LPMWs. Comparisons within each age group are shown. 
Differences between women with versus without LPMWs are indicated (*). 
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6.5 Discussion 
 In the present study, we characterized endocrinologic changes associated with follicle 
wave dynamics in women of advanced reproductive age compared to women of reproductive 
age. Increased estradiol, but not inhibin A, was associated with an increased incidence of 
polyovulation in the ARA2 versus RA group. Half of the LPMWs were associated with 
atypically high estradiol and decreased luteal progesterone in the ARA2 group. No difference in 
inhibin A was detected in women with or without LPMWs which was similar to FPMWs. 
Greater inhibin B, but not AMH, was detected only in the RA women with versus without 
LPMWs. Thus, our hypotheses were partially supported.   
 
6.5.1 Luteal Phase Major Waves (LPMWs) 
 Luteal phase major waves developed in approximately 50% of women evaluated; the 
prevalence of LPMWs did not change with age. Luteal phase major waves associated with 
atypically high estradiol secretion were detected prior to noticeable changes in menstrual 
cyclicity in 2/4 women of advanced reproductive age. The prevalence of LPMWs in reproductive 
age women in this study was greater than previous reports (33, 103). The greater prevalence of 
LPMWs in the present study compared to previous reports may have been attributed to a small 
sample size, differences in participant demographics,  lifestyle factors (i.e. diet, exercise) and/or 
environmental influences (i.e. season, urban versus rural setting) not fully understood. 
 In contrast to the prevalence of LPMWs across age groups, the growth dynamics of 
LPMWs did change as women aged. Specifically, the LPMWs emerged earlier (6 versus 2 days 
before ovulation) in the ARA2 versus RA groups. The largest 1-2 follicles of LPMWs at 
advanced reproductive age had already achieved dominance at the time of the pre-ovulatory 
 87 
gonadotropin surges, and then appeared to respond to rising FSH and LH in the early luteal 
phase. The dominant follicle(s) continued to grow to large, often cystic, diameters (range: 10.0-
37.0 mm) and persisted into the late luteal and sometimes early-mid follicular phase. In 
comparison, LPMWs in the RA group achieved dominance (diameter range:10.0-16.0 mm) and 
regressed before the emergence of the subsequent FPMW (270). Atypical elevations in estradiol 
were detected in half of the ARA2 women with LPMWs. In general, we found the larger the 
dominant follicle, the higher the estradiol and lower the peak LH concentrations. Serum luteal 
phase estradiol was higher, but not atypically high (i.e., >200 pg/mL), in RA women with versus 
without LPMWs and in the remaining 4/8 ARA2 women with LPMWs. 
 There are several reports of an inverse relationship between luteal phase estradiol and 
progesterone during the MT in women (6, 10, 151, 182) as well as in domestic farm animals 
(272, 273).  However, the physiological mechanisms for this relationship were not understood. In 
the present study, progesterone concentrations were not different between women with versus 
without LPMWs in the RA group. However, in the ARA2 group, progesterone was lower in 
women with versus without LPMWs. It is possible that atypically high estradiol in the luteal 
phase in the older women may have had a suppressive effect on luteal progesterone production. 
It is further plausible that the timing of the atypical rise in estradiol influenced its potential effect 
on luteal function. An early rise in luteal phase estradiol was associated with lower progesterone 
production; however, a similar observation was not made when estradiol was elevated in the 
mid-late luteal phase. In contrast to estradiol, luteal phase inhibin A was not different in women 
with versus without LPMWs in either age group. These data suggest that dominant follicles of 
LPMWs do not contribute to luteal phase inhibin A production. Alternatively, it is possible that 
dominant follicle production of inhibin A in the luteal phase may be influenced or masked by 
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production of inhibin A by the CL. Further research is required to determine if and why 
dominant follicles from luteal versus follicular phase major waves differentially produce inhibin 
A.  
 All but one LPMW was anovulatory. In one woman of advanced reproductive age, an 
ovulatory LPMW was observed. The ovulatory LPMW emerged 5 days before the first ovulation 
of the IOI and grew throughout the luteal phase in association with atypically high 
concentrations of estradiol in the late luteal phase. The LPMW ovulated during menses, followed 
by a rapid drop in estradiol. A second CL was observed in associated with a second rise in 
progesterone in the follicular phase.  We believe that the high estradiol concentration from the 
LPMW dominant follicle triggered an LH surge in the early follicular phase, once the inhibitory 
actions of progesterone were removed. However, due to sampling frequency, we did were unable 
confirm the presence of a follicular phase LH surge. Ovulation in the early follicular phase has 
been shown endocrinologically in women undergoing the MT (10). 
 In the present study, early follicular phase elevations in estradiol were attributed to the 
development of functional dominant follicles persisting from LPMWs. These findings contradict 
those of previous studies in which early follicular phase estradiol elevations were postulated to 
originate from either earlier (153, 193) or accelerated (172, 192) follicular phase follicle 
development. Moreover, luteal progesterone was greater in the ARA2 versus RA groups, due to 
a greater frequency of polyovulations from the FPMW. Increased luteal progesterone 
concentrations have been reported in women of advanced reproductive age previously (6, 153).  
 In reproductive age women, the occurrence of LPMWs was positively associated with 
AFC >6 mm and inhibin B. Women in the RA group with LPMWs had a greater mean AFC 
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>6mm and inhibin B over the IOI compared to those without LPMWs. Similarly, individual AFC 
profiles for follicles >6 mm over the IOI closely resembled those of inhibin B. Inhibin B is 
produced by antral follicles 3-12 mm, and peak at a diameter of approximately 9mm (48). Thus, 
LPMWs were more likely to develop when a greater number of follicles were recruited into a 
wave. AMH concentrations were not associated with the development of LPMWs. However, we 
anticipate that the development of more sensitive AMH assays will allow the conduct of future 
studies to confirm a relationship between AMH and the development of LPMWs as women age.  
6.5.2 Follicular Phase Major Waves (FPMWs) 
 Follicular phase major waves were detected in all women during the study with the 
exception of one woman in the ARA2 group. FPMWs consistently emerged at the time of 
menses onset (i.e., 13-14 days post ovulation) in RA and ARA2 women, and resulted in 
ovulation. We interpreted these findings to mean that the timing of FPMW emergence in 
ovulatory cycles appears relatively uniform as women progress from reproductive to advanced 
reproductive age.  
 In the ARA2 group, FPMWs developed under the influence of elevated FSH as well as  
lower inhibin B and AMH, consistent with previous reports (5, 191, 193). FPMWs during 
advanced reproductive age were associated with greater estradiol (but not inhibin A) production. 
Thus, our hypothesis that elevated follicular phase estradiol and inhibin A would be a result of an 
increased incidence of codominance and/or polyovulation was only partially supported. Greater 
follicular phase estradiol has been previously postulated to relate to a greater incidence of 
codominance and polyovulation (182, 274). The results of our research support this notion. We 
believe that the polyovulation occurred in women of advanced reproductive age due to the loss 
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of inhibin B-mediated negative feedback to FSH, which then widens the FSH window thereby 
allowing more than one follicle to become dominant (74, 265).  
6.5.3 Limitations and Future Directions 
This pilot study was conducted to characterize age-related change in major follicular 
wave dynamics and associated hormone production. Comparing follicular and endocrine 
dynamics across age groups was a logical starting point to test our hypotheses.  However, 
harmonized clinical and scientific criteria have recently been developed to characterize the stages 
of reproductive aging  (i.e., Stages of Reproductive Aging Workshops (STRAW) criteria) (122). 
The STRAW stages of reproductive aging are based on changes in menstrual cyclicity, hormone 
production and antral follicle count (i.e., AFC) that occur in women throughout the reproductive 
lifespan (122). When datasets from our study were categorized by STRAW criteria, we found 
that  only 5/17 (30%) women in the ARA2 group were considered to be in the early or late MT. 
The remaining 12/17 (70%) were determined to be in late reproductive STRAW stages. The low 
proportion of women in the ARA2 group that had entered the MT was attributed, in part, to the 
evaluation of ovulatory but not anovulatory cycles. We further attempted to compare follicle 
development and hormone production across STRAW categories of reproductive aging.  
However, our relatively small sample sizes provided inadequate power to form meaningful 
conclusions. Therefore, the next step in our research program is to characterize follicle and 
corresponding hormone dynamics in women during STRAW stages of reproductive aging. The 
long-term goal of research in this area is to increase our understanding of the physiologic 
changes that lead to atypical hormone production and changes in menstrual cyclicity as women 
approach menopause. 
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The role of AMH in regulating human antral folliculogenesis is not understood. In 
women of advanced reproductive age, there were several instances where concentrations of 
inhibin A, inhibin B, and/or AMH were at or below the sensitivity of the assays. Continued 
research is required to develop more sensitive AMH and inhibin assays in order to investigate the 
roles of these hormones in regulating age-related changes in follicle dynamics.  
6.5.4 Clinical Applications  
 Documentation of functional (i.e., estrogenic) luteal phase dominant follicles has clinical 
applications for optimizing fertility therapies in cancer patients. Results of preliminary studies 
have shown that luteal phase oocyte retrieval in patients requiring urgent treatment prior to 
chemotherapy resulted in development of healthy, viable embryos (109). Collectively, findings 
from the previously mentioned study (49) and the present study suggest that it may be possible to 
initiate ovarian stimulation in all fertility patients at both the early follicular and early luteal 
phases of the cycle.  
The combination of serial ultrasonographic and endocrinologic data provides insight into 
the origins of atypical hormone production in women of advanced reproductive age. These 
findings are clinically relevant because aberrant fluctuations in estradiol during the MT have 
been speculated to be associated with the development of vasomotor symptoms, which can have 
a significant and negative impact on a women’s quality of life. Furthermore, exposure to 
unopposed estradiol has been shown to place women at increased risk for endometrial cancer 
(201, 275). Information about the follicular origins of variability in hormone production during 
the MT is essential for understanding the pathophysiology of unpredictable and debilitating 
symptoms experienced by women as they age. Increased knowledge about ovarian aging also has 
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implications for providing insight into the origins of age-related risks for cardiovascular disease, 
cognitive dysfunction, and declining musculoskeletal health (8, 188, 275, 276). 
6.5.5 Summary 
 FPMWs developed in 94-100% of women, while LPMWs occurred in 30-50% of 
women; the prevalence of FPMWs and LPMWs did not change with age. The timing of 
emergence of FPMWs appeared uniform as women progressed from reproductive to advanced 
reproductive age, despite reduced AMH and inhibin B and increased FSH. In contrast, the 
growth and endocrine dynamics of LPMWs markedly changed with age. LPMWs emerged 
earlier, grew longer, and to a larger diameter in association with atypically high estradiol and 
decreased serum progesterone in women of advanced reproductive age. It appears that the fall in 
inhibin B, AMH, and resultant rise in FSH that occurs with age enables the development of 
large, estrogenic, luteal phase dominant follicles. The relationship between acute elevations in 
luteal phase estradiol secretion and suppression of progesterone production requires further 
investigation. A greater understanding about the relationships between follicle wave dynamics 
and hormone production and unwanted symptoms (i.e., vasomotor symptoms) during the MT 
will provide valuable insight into the development of safe and effective therapies for alleviating 
vasomotor symptoms.  
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Chapter 7 
GENERAL DISCUSSION 
 In the studies presented in this thesis, age-related changes in human antral 
folliculogenesis and reproductive hormone concentrations were characterized. Major follicle 
wave dynamics were compared across a single IOI in women of reproductive age (RA: 18-35 
years, n=27) and advanced reproductive age (ARA1: 36-44 years, n=10; ARA2: 45-55 years, 
n=21). Hormone production associated with major follicle wave dynamics was evaluated in a 
subset of women in the RA group (n=10) and ARA2 group (n=17). The RA group was chosen to 
represent a reference group of ovulatory women in the peak reproductive stage of life. The 
ARA1 group represented ovulatory women during the late reproductive stage of life. The ARA2 
age group was chosen to represent ovulatory women undergoing the transition to menopause.  
 We are the first to characterize concurrent and serial changes in ultrasonographic (i.e., 
morphologic) and endocrine characteristics of ovarian function as women age. Previous studies 
conducted to characterize reproductive aging and the transition to menopause have been based 
on urinary or serum endocrine data and/or changes in menstrual cyclicity with follicle data 
restricted mainly to the selected preovulatory follicle. A decline in AFC, AMH and inhibin B 
were detected with age in association with a rise in FSH, as previously reported. Major waves of 
follicle development were detected in both the follicular and luteal phases of the IOI. Ovulatory 
FPMWs occurred in 95-100% of women and LPMWs occurred in 30-50% of women. The 
prevalence of LPMWs and FPMWs did not change with age. However, the growth dynamics of 
follicular and luteal phase major waves did change with age. Therefore, our general hypothesis 
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that changes in major follicle wave dynamics and hormone production would occur with age was 
supported.  
 Our data supported the theory that depletion of the ovarian reserve is responsible for 
altering the activity of the hypothalamic-pituitary-axis which then initiates the physiologic 
changes that occur as women enter the transition to menopause (175). This theory of an ovarian 
origin of reproductive aging contrasts the notion that a deterioration in the ‘biological clock’ in 
the suprachiasmatic nucleus of the hypothalamus results in altered GnRH release and 
gonadotropins secretion that occurs with entrance in the MT (180, 277, 278). However, we did 
not specifically evaluate hypothalamic and/or pituitary sensitivity to reproductive hormones.   
7.1 Luteal Phase Major Waves 
 Although the prevalence of LPMWs did not change, the growth dynamics and hormone 
production were markedly different between age groups. The dominant follicle(s) of the LPMWs 
emerged earlier, grew longer, and to a larger diameter in women of advanced reproductive age 
(>45 years old). We were able to determine the exact day of emergence of LPMWs in 7/10 
women with LPMWs in the ARA2 group. Of the 7 LPMWs, 5 emerged in the mid-follicular 
phase (day -6 to -4; day 0 = ovulation) of the preceding cycle. The remaining 2 LPMWs emerged 
around the time of ovulation (day -1 to 2; day 0 = ovulation). The timing of emergence of 
follicular, but not luteal phase, major waves has been previously investigated. No evidence of 
mid- to late- follicular phase emergence of the luteal phase major wave has been demonstrated in 
animal models. Therefore, the mid-late follicular phase emergence of the LPMW is a unique 
finding in women of advanced reproductive age in our study. It is plausible that the dominant 
follicles from LPMWs in older women emerged from a follicular versus a luteal phase wave. 
 95 
Evidence of minor waves emerging in the mid-late follicular phase (i.e., at the time of selection) 
has been obtained in mares (279) and women (6). We believe that the decreased inhibin B from 
the reduced follicular pool and resultant rise in FSH led to the emergence of major waves in the 
mid-late follicular phase (despite the suppressive effects of estradiol from the dominant follicle). 
The lack of sufficient FSH suppression during the mid-late follicular phase may reflect a 
combination of reduced hypothalamic responsiveness to estradiol and/or decreased inhibin B 
production from antral follicles of the wave. From limited studies, it has been shown that 
reduced hypothalamic/pituitary responsiveness to estradiol occurs in the later stages of 
reproductive aging (180). Therefore, it is plausible that estradiol from the dominant follicle of the 
FPMW may be unable to exert its suppressive effects of FSH production due to reduced 
hypothalamic/pituitary responsiveness with reproductive aging. It is further plausible that AMH 
(which is declining with age) may enhance the sensitivity of follicles to FSH. AMH has been 
shown previously to suppress granulosa cell FSH-induced aromatase activity (56, 87). However, 
it is unclear if intrafollicular concentrations of AMH in similar sized follicles decline in women 
of advanced versus reproductive. Continued research is needed to elucidate whether AMH has an 
autocrine or paracrine role within the ovary with reproductive aging.  
 The sensitivity of the AMH assay became a limiting factor in comparing AMH in women 
with versus without LPMWs. The largest follicle of the LPMW had already achieved dominance 
at the time of the preovulatory gonadotropin surge (i.e., ovulation #1 of the IOI). Therefore, we 
believe that the LPMW dominant follicle likely had acquired the cellular machinery (i.e., 
aromatase enzyme activity and LH receptors) which allowed it to respond to the FSH and LH 
surge and continue to grow to a preovulatory or cystic diameter in the subsequent luteal phase. In 
all women of reproductive age, the LPMWs were growing in association with developing CL, 
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therefore we believe did not have the machinery to respond to the LH surge like the dominant 
follicles of the LPMWs in women of advanced reproductive age. In reproductive-age women, 
LPMWs were associated with high (but not atypically high) estradiol. However, in women of 
advanced reproductive age, LPMWs were associated with atypically high estradiol. We were not 
able to directly measure the follicular versus luteal contributions of estradiol or inhibin A in the 
present study. However, we observed that the larger the LPMW dominant follicles grew, the 
more estradiol was produced in the luteal phase. Half (4/8) of the LPMWs in the ARA2 group 
developed in association with atypically high estradiol secretion. We interpret these data to 
confirm previous speculations (7) that atypical elevations in luteal phase estradiol during the MT 
originate from age-related changes in major follicle wave dynamics. Thus, our hypotheses were 
further supported. 
 Luteal phase progesterone concentrations were higher overall in the ARA2 versus RA 
groups. These findings were due to a greater incidence of polyovulation, and multiple luteal 
glands, in the ARA2 group. Polyovulations did not occur in the RA group. However, when data 
were further stratified, we found that women of advanced reproductive age with LPMWs had 
lower luteal progesterone concentrations compared to those that did not have LPMWs even after 
cycles with multiple CLs were removed. We interpret these findings to suggest that follicular 
estradiol may have a suppressive effect on luteal function. Luteolytic effects of estradiol have 
been demonstrated in domestic farm animals (8, 9). Similarly, inverse relationships between 
luteal phase estradiol and progesterone have been reported previously during the MT (6, 10). 
After closer inspection of individual profiles, we observed that earlier acute luteal phase 
increases in estradiol appeared to be associated with lower progesterone whereas mid- to late- 
luteal phase increases estradiol were not. Thus, we believe that the timing of the acute increase in 
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estradiol may influence its potentially suppressive effect on luteal development similar to reports 
in domestic farm animals (272, 273, 280). In both the RA and ARA2 groups, LPMW dominant 
follicle peak diameter was inversely related to peak luteal phase LH concentrations. In the 
presence of progesterone, estradiol has a suppressive effect on LH secretion. Thus, we believe 
that the acute increase in luteal phase estradiol further suppressed LH production. This may also 
explain why all but one of the LPMWs with atypically high estradiol production failed to 
ovulate. In one woman of advanced reproductive age, a LPMW was able to grow (in the 
presence of a CL) and ovulate in the early follicular phase following luteal regression. An LH 
surge was not confirmed due to the frequency of blood sampling.  However, a second rise in 
progesterone was detected following ultrasonographic documentation of follicle rupture. The 
physiologic mechanisms allowing some but not all LPMWs to ovulate are not known. We 
speculate that the acute increase in estradiol production from the luteal phase dominant follicle 
was able to stimulate an LH surge which then resulted in ovulation. Not all LPMWs resulted in 
atypically high estradiol production. However, atypically high luteal estradiol production was 
only observed in association with LPMWs. Documentation of ovulation at the time of menses in 
women has clinical implications for understanding contraceptive needs of women as they 
approach menopause.  
 In summary, LPMWs in women of advanced reproductive age may have one of the 
following 3 fates: 
Type I  Emergence around the time of ovulation, normal estradiol and progesterone  
production, resulting in anovulation (both participants had a 26 day IOI (n=2));  
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Type II  Mid/late follicular phase emergence, normal estradiol and progesterone   
  production, resulting in anovulation (the IOIs ranged from 26-30 days (n=2)); or, 
Type III  Mid/late follicular phase emergence associated with atypically high estradiol,    
lower progesterone, resulting in either ovulation or anovulation (the IOIs ranged 
from 17-41 days (n=4)). 
 A proposed model of the endocrine changes from the depletion of the ovarian reserve 
associated with reproductive aging and the consequences on luteal phase major wave emergence 
are depicted in Figure 7.1. 
Figure 7.1: A proposed model of the morphologic and endocrinologic changes which occur 
during reproductive aging. Dashed lines around follicles indicate a pattern of follicle 
development occurs in some women. A: A 3rd anovulatory major wave occurs in some 
 99 
reproductive aged women (not shown). Modified from Broekmans et al., 2009 (167), Soules et 
al., 1998 (176), and Baerwald et al (33). 
7.2 Follicular Phase Major Waves 
 In contrast to LPMWs, fewer differences in the growth dynamics of FPMWs were 
detected. The day of wave emergence, day of selection, diameter at selection, and preovulatory 
diameter in the FPMW were similar among age groups. No obvious differences in the growth 
interval of the FPMW dominant follicle were detected between groups. The lack of differences 
in timing of emergence, day of selection, and preovulatory diameter of the FPMW across age 
groups contrasts findings from previous studies (153, 193, 194, 210, 211). We believe that 
underlying minor patterns of follicle development occur across the menstrual cycle/IOI. It is 
plausible that the endocrine environment resulting from follicle and/or luteal development in the 
luteal phase determines the timing of FPMW emergence and whether a minor wave will develop 
into a major wave. In previous studies, indirect assessments of follicular development based on 
hormone changes and/or ultrasonographic data limited to the dominant preovulatory follicle were 
made.  In contrast, we assessed serial changes in the growth dynamics of individually-identified 
follicles over an entire IOI. Therefore, differences in methodology may have contributed to the 
variation among reported findings. Categorization of data by age in the studies discussed versus 
the degree of menstrual cycle (ir)regulatory and stage of reproductive aging in other studies may 
have further contributed conflicting results. We identified two possible sources of elevated 
estradiol in the follicular phase. Polyovulatory cycles only occurred in the ARA2 group, 
consistent with previous studies (192, 194, 196). Polyovulatory FPMWs in the ARA2 group 
were associated higher maximum (i.e., preovulatory) follicular phase estradiol, supporting 
previous speculation (182). Early elevated follicular phase estradiol has been previously 
attributed to earlier (153, 193) or accelerated (172, 192) dominant follicle growth. However, we 
 100 
were able to document that early follicular phase estradiol (i.e., day 2-4) was also associated with 
development of estrogen-producing LPMWs persisting into the early follicular phase, as opposed 
to earlier emergence of the FPMWs reported from other investigators(153, 193, 194). We found 
that subordinate follicles grew to smaller diameters with reproductive aging, similar to domestic 
farm animals (211). It is plausible that a smaller number of follicles within a wave may limit the 
diameter to which subordinate follicles can develop.  
7.3 Major Follicular Wave Dynamics and Menstrual Cyclicity 
 Unique patterns of follicle development were characterized during ovulatory cycles in the 
ARA2 group, consistent with previous research (1, 5, 6). An abnormally short IOI was detected 
in one participant which resulted from the development of an ovulatory LPMW. In contrast, 
abnormally long IOIs occurred due to the presence of lag phases. Previous investigators have 
characterized lag phases as times of temporary ovarian non-responsiveness to pituitary 
stimulation by FSH and resulting lack of estradiol production (155, 198). It was hypothesized 
that an increased rate of atresia, slowed early antral follicle growth, or a lack of available 
follicles accounted for the limited endocrine activity in a lag phase (155, 198, 199). We observed 
a lack of follicle development beyond 6 mm during lag phases in association with elevated FSH 
and LH. Major and minor waves of follicle growth have been characterized in follicles >5mm; 
however, major waves were those in which growth proceeded beyond 6 mm and a dominant 
follicle was selected at approximately 10 mm (70). We concluded that major waves of follicle 
development did not occur during lag phases. Minor waves may have emerged during the lag 
phase; however, minor waves were not characterized in this study.  
 
 101 
 
7.4 The Influence of Ovarian Reserve on the Development of LPMWs  
 The factors which determine whether or not a LPMW develops remain poorly elucidated. 
We observed that reproductive age women with a higher AFC > 6 mm and greater inhibin B 
were more likely to develop LPMWs. Thus, a greater number of follicles available for cyclic 
emergence into a wave increased the likelihood of developing a LPMW in reproductive age 
women. To our surprise, no differences in AFC 2-9 mm and serum AMH were detected in 
women of reproductive age. However, it is possible that the inability to detect a difference in 
AFC 2-9 mm and AMH in women with versus without LPMW was related to limitations in the 
sensitivity of AMH assays and the inability to reliably detect serial changes in antral follicles < 
4mm. The relationship between LPMWs, AFC, and ovarian reserve is not fully understood. 
7.5 Future Directions and Clinical Applications 
 Age-related changes in major follicle wave dynamics were evaluated in the present study. 
However, minor waves were not characterized. The age-related decline in the number of antral 
follicles, frequency of data collection (i.e., 1-3 days), and sensitivity of ultrasonography in the 
present study limited our ability to reliably characterize minor waves. We observed the 
emergence of minor waves every 4-6 days throughout the IOI in reproductive age women which 
appeared to underlie the development of major waves. We believe that the follicles recruited into 
the LPMWs in women of advanced reproductive age may originate from an underlying minor 
wave that emerged in the mid follicular phase of the preceding cycle. Emergence of minor waves 
at the time of selection has been observed previously by our group (unpublished data) and also in 
mares (279). The development of novel techniques such as ultrasound biomicroscopy for in vivo 
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use and improved ultrasound technology may further enable research to characterize minor 
waves of antral folliculogenesis in women. 
 Categorization of our data by age was a logical starting point to characterize changes in 
follicular dynamics as women approach menopause. We recruited women in age groups which 
have been shown to represent the peak reproductive (RA), late reproductive (ARA1), and the 
menopausal transition (ARA2) stages of life (2, 150).Women with either regular or irregular 
cycles were recruited into the ARA2 group. However, only ovulatory cycles were evaluated. 
Ovulatory and anovulatory cycles are a feature of the MT however the prevalence of anovulatory 
cycles increases as the MT progresses. We believe that exclusion of anovulatory cycles in our 
study prevented us from including women in the later stages of the MT. We observed that only 
30% were found to be in the MT when we categorized data by STRAW criteria for menstrual 
cyclicity (122). It was not possible to analyze our data according to STRAW categories as the 
resultant small sample size (27 women distributed over 5 categories of reproductive life) did not 
provide enough statistical power to test our hypotheses. Therefore, future studies should be 
conducted to characterize follicle wave dynamics in both ovulatory and anovulatory cycles 
across the different STRAW stage of reproductive aging.  
 The serum concentrations of inhibin A, B, and AMH in women of the ARA2 group were 
frequently at, or below, the sensitivity of the assays.  As a result, we were not able to characterize 
serial changes in AMH concentrations in all of the older women. The development of more 
sensitive AMH assays is critical for elucidating the role of AMH in regulating antral follicle 
wave dynamics.  
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 Hormone therapy (HT) is used by women during the MT to treat unwanted symptoms 
(i.e., vasomotor symptoms, night sweats, vaginal dryness) and to prevent complications related 
to the low estrogen (i.e., osteoporosis) (281). LPMWs are a source of atypically high estradiol as 
women age. Future research should be conducted to study relationships between atypically high 
estradiol production associated with the development of LPMWs, unwanted symptoms, and 
endometrial hyperplasia. A greater understanding of the pathophysiology of unwanted symptoms 
and age-related increased risks for endometrial hyperplasia will enable the development of novel 
therapies for preventing and/or treating these debilitating adverse events. The discovery of 
inhibin B and its direct role in regulating follicle growth dynamics via FSH offers an exciting 
avenue to explore a potential new line of therapy for suppressing follicle growth. A detectable 
decline in inhibin B occurs in the fourth decade of a women’s life (170, 172, 173). Impaired 
folliculogenesis and aberrant hormone production begins following the decline in inhibin B. We 
propose that incorporating inhibin B into a hormone therapy regimen may be an effective way to 
suppress aberrant follicle growth without incurring the same health risks associated with long-
term estrogen supplementation (282).  
 In summary, major waves of follicle development occur in ovulatory cycles throughout 
the reproductive lifespan. The depletion of the ovarian reserve as women age results in a decline 
in inhibin B, rise in FSH, a consequent alteration in follicle wave dynamics and resulting atypical 
production of estradiol and progesterone during the menstrual cycle. The growth dynamics of 
FPMWs remains fairly constant as women age with exception of an increased incidence of 
polyovulation and smaller subordinate follicles. However, the growth dynamics of LPMWs 
markedly changed with age. In women of advanced reproductive age, LPMWs emerged earlier, 
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grew longer and to a larger diameter, in association with atypical elevations in luteal phase 
estradiol and lower luteal phase progesterone compared to women without LPMWs.  
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Chapter 8 
GENERAL CONCLUSIONS 
 
 The results of the studies presented in this thesis have led to the conclusion that follicle 
wave dynamics and associated hormone production change as women age. The specific 
conclusions are listed below.  
1. Waves of follicle development occur in both the follicular and luteal phases of the IOI. 
The prevalence of major follicles waves does not change as a woman ages.  
Approximately 95-100% of women develop FPMWs and 30-50% of women develop 
LPMWs. 
2. An increased incidence of polyovulation and smaller subordinate follicles in FPMWs 
occurs with age. 
3. The growth dynamics of LPMW and associated hormone production change with age: 
a. LPMWs may be anovulatory or ovulatory in women of advanced reproductive 
age; 
b. LPMWs emerge earlier, grow longer and to a larger diameter in women of 
advanced reproductive age compared to those of reproductive age; and,  
c. In 50% of women of advanced reproductive age, atypically high luteal phase 
estradiol and low (but not atypical) progesterone occur in association with the 
development of LPMWs. 
4. In women of reproductive age, an increased AFC >6mm and inhibin B (which indicates a 
greater number of follicles available for recruitment into a wave) are more likely to 
develop LPMWs.  
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